Antibody binding to fibrin, fibrin-soluble protein containing same, and pharmaceutical preparation

By modifying the amino acid sequence of the fusion protein and optimizing the culture conditions, the stability and purification problems in the production of fibrinolytic proteins were solved, achieving efficient and low-cost fibrinolysis.

CN118922548APending Publication Date: 2024-11-08RIN INST INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031794.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-10-05
Filing Date
2023-04-07
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the existing technology, the manufacturing process of fibrinolytic proteins has problems such as increased upper limit of production, generation of protein decomposition products, need for serum and specific additives, and the fusion protein does not bind to human urokinase receptor.

Method used

By modifying the amino acid sequence of the fusion protein, especially by replacing specific amino acids of prourokinase, such as replacing phenylalanine at position F157 with other amino acids, such as glutamic acid or aspartic acid, the binding ability to human urokinase receptor is reduced, and the protein is cultured and purified under serum-free or low-serum conditions to improve its stability.

Benefits of technology

This approach improved the stability of the fusion protein, reduced its binding affinity to the human urokinase receptor, decreased the proportion of light chains generated, lowered production costs, and improved purification efficiency and product yield.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

Provided are: a stable fibrous protein clot-soluble protein which is produced in protein-expressing cells in a serum-free medium and which is suppressed in the production of impurities such as degradation products; a pharmaceutical preparation containing the protein; and a method for producing the protein and the pharmaceutical preparation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an antibody that binds to fibrin, a fibrinolytic protein containing the antibody, and a pharmaceutical preparation containing the protein. The present invention particularly relates to a fibrinolytic protein suitable for large-scale purification and a pharmaceutical preparation containing the protein. The present invention also relates to a method for stabilizing a fibrinolytic protein and a method for producing a stabilized fibrinolytic protein. Background Art

[0002] Antibodies that bind to fibrin with a stronger affinity than to fibrinogen have been developed (Patent Documents 1 and 2). These patent documents disclose the use of such antibodies for cancer treatment. Antibodies that strongly bind to fibrin can also be used for in vivo imaging (Patent Documents 1 and 2).

[0003] In addition, a fusion protein of an antibody that binds to fibrin and a pro-urokinase mutant was developed and disclosed to have a thrombolytic effect (Patent Document 3).

[0004] Prior art literature

[0005] Patent Literature

[0006] Patent Document 1: WO2014 / 133093

[0007] Patent Document 2: WO2018 / 203517

[0008] Patent document 3: WO2021 / 200922 Summary of the invention

[0009] The present invention provides antibodies bound to fibrin, fibrinolytic proteins containing the antibodies, and pharmaceutical preparations containing the proteins. Specifically, the present invention, which clarifies the problems of a large number of manufacturing in WO2021 / 200922 (patent document 3) (for example, the problem of increasing the upper limit of the amount of production in protein-producing cells, the problem of producing the degradation products of the generated protein, the problem of requiring serum in culture, the problem of requiring specific additives in purification, and the problem of unexpected activation, etc.), can alleviate or solve any one or more of the above problems in one way. In addition, the fusion protein disclosed in patent document 3 does not bind to the mouse urokinase receptor, but shows reactivity to the human urokinase receptor. In one embodiment of the present invention, the reactivity to the human urokinase receptor can be reduced or eliminated.

[0010] According to the present invention, the following inventions are provided.

[0011] [1] A fusion protein comprising an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin and a catalytic domain of prourokinase having an amino acid sequence corresponding to the amino acid sequence from positions 156 to 411 of prourokinase as set forth in SEQ ID NO: 6 or 7, wherein the antibody or the antigen-binding fragment thereof is linked to the catalytic domain of prourokinase directly or via a linker, wherein:

[0012] The antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region of an antibody that binds to insoluble fibrin,

[0013] The phenylalanine in the catalytic domain corresponding to the phenylalanine at position 157 of pro-urokinase described in SEQ ID NO: 6 or 7 is substituted with another amino acid.

[0014] [2] The fusion protein according to [1] above, wherein the phenylalanine is substituted with isoleucine, glutamic acid, aspartic acid or cysteine.

[0015] [3] The fusion protein according to [1] or [2] above, wherein the phenylalanine is substituted with glutamic acid or aspartic acid.

[0016] [4] The fusion protein according to any one of [1] to [3] above, wherein the ability to bind to one or more urokinase receptors selected from the group consisting of human urokinase receptor and mouse urokinase receptor is reduced compared to the fusion protein having the amino acid sequence described in SEQ ID NO: 1.

[0017] [5] The fusion protein according to any one of [1] to [4] above, which does not show significant binding to one or more urokinase receptors selected from the group consisting of human urokinase receptor and mouse urokinase receptor.

[0018] [6] A fusion protein according to any one of [1] to [3] above, wherein an EGF-like domain having an amino acid sequence corresponding to the amino acid sequence of positions 7 to 43 of pro-urokinase recorded in SEQ ID NO: 6 or 7 is further contained between the antibody or antigen-binding fragment thereof and the catalytic domain, and the amino acids of the EGF-like domain corresponding to asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30 and glutamine at position 40 of pro-urokinase recorded in SEQ ID NO: 6 or 7 are replaced by other amino acids, thereby reducing or losing the ability to bind to the human urokinase receptor.

[0019] [7] A fusion protein according to any one of [1] to [4] above, wherein an EGF-like domain having an amino acid sequence corresponding to the amino acid sequence of positions 7 to 43 of pro-urokinase recorded in SEQ ID NO: 6 or 7 is further contained between the antibody or antigen-binding fragment thereof and the catalytic domain, and the amino acids of the EGF-like domain corresponding to asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30 and glutamine at position 40 of pro-urokinase recorded in SEQ ID NO: 6 or 7 are replaced by tyrosine, serine, arginine, arginine and glutamic acid, respectively, and the ability to bind to the human urokinase receptor is reduced or lost.

[0020] [8] A fusion protein according to any one of [1] to [4] above, wherein an EGF-like domain having an amino acid sequence corresponding to the amino acid sequence of positions 7 to 43 of pro-urokinase recorded in SEQ ID NO: 6 or 7 is contained between the antibody or antigen-binding fragment thereof and the catalytic domain, and the amino acid sequence of the EGF-like domain corresponding to the amino acids from asparagine at position 22 to isoleucine at position 28 of pro-urokinase recorded in SEQ ID NO: 6 or 7 is deleted.

[0021] [9] A pharmaceutical preparation comprising the fusion protein according to any one of [1] to [8] above.

[0022]

[10] A method for producing the fusion protein described in any one of [1] to [8] above, comprising the steps of: culturing a protein-producing cell having a nucleic acid encoding the fusion protein in an expressible manner to express the fusion protein; and purifying the fusion protein from the obtained culture.

[0023]

[11] The method according to

[10] above, wherein the culture is carried out in the absence of serum or in the presence of less than 5% serum.

[0024]

[12] The method according to

[10] or

[11] above, wherein the purification is performed in the absence of L-arginine.

[0025]

[13] A method for producing a fusion protein modification (preferably one with excellent stability) or a pharmaceutical composition containing the modification, wherein:

[0026] The fusion protein is a fusion protein comprising an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin and a catalytic domain of prourokinase having an amino acid sequence corresponding to the amino acid sequence from positions 156 to 411 of prourokinase described in SEQ ID NO: 6 or 7, wherein the antibody or the antigen-binding fragment thereof and the catalytic domain of prourokinase are linked directly or via a linker,

[0027] The antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region of an antibody that binds to insoluble fibrin,

[0028] The method comprises the following steps: introducing F157E or F157D mutation into the fusion protein, thereby conferring better stability than the fusion protein before the modification.

[0029]

[21] A fusion protein comprising an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin and a catalytic domain of prourokinase having an amino acid sequence corresponding to the amino acid sequence from positions 156 to 411 of prourokinase as set forth in SEQ ID NO: 6 or 7, wherein the antibody or the antigen-binding fragment thereof is linked to the catalytic domain of prourokinase directly or via a linker, wherein the fusion protein comprises:

[0030] The antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region of an antibody that binds to insoluble fibrin,

[0031] An EGF-like domain having an amino acid sequence corresponding to the amino acid sequence of positions 7 to 43 of pro-urokinase recorded in sequence number 6 or 7 is also contained between the above-mentioned antibody or its antigen-binding fragment portion and the catalytic domain portion, and the amino acids of the above-mentioned EGF-like domain corresponding to asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30 and glutamine at position 40 of pro-urokinase recorded in sequence number 6 or 7 are replaced by other amino acids, and the binding ability to the human urokinase receptor is reduced or lost.

[0032]

[22] A fusion protein comprising an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin and a catalytic domain of prourokinase having an amino acid sequence corresponding to the amino acid sequence from positions 156 to 411 of prourokinase as set forth in SEQ ID NO: 6 or 7, wherein the antibody or the antigen-binding fragment thereof is linked to the catalytic domain of prourokinase directly or via a linker, wherein the fusion protein comprises:

[0033] The antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region of an antibody that binds to insoluble fibrin,

[0034] An EGF-like domain having an amino acid sequence corresponding to the amino acid sequence of positions 7 to 43 of pro-urokinase recorded in sequence number 6 or 7 is also contained between the above-mentioned antibody or its antigen-binding fragment portion and the catalytic domain portion, and the amino acids of the above-mentioned EGF-like domain corresponding to asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30 and glutamine at position 40 of pro-urokinase recorded in sequence number 6 or 7 are replaced by tyrosine, serine, arginine, arginine and glutamate, respectively, and the binding ability to the human urokinase receptor is reduced or lost.

[0035]

[23] A fusion protein comprising an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin, an EGF-like domain of prourokinase having an amino acid sequence corresponding to amino acids 7 to 43 of prourokinase as described in SEQ ID NO: 6 or 7, a kringle domain of prourokinase corresponding to amino acids 49 to 131, and a catalytic domain of prourokinase having an amino acid sequence corresponding to amino acids 156 to 411, wherein the antibody or the antigen-binding fragment thereof is linked to the catalytic domain of prourokinase directly or via a linker, wherein the fusion protein:

[0036] The connector is a non-cleavable connector.

[0037] The antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region of an antibody that binds to insoluble fibrin,

[0038] An EGF-like domain having an amino acid sequence corresponding to the amino acid sequence of positions 7 to 43 of pro-urokinase recorded in sequence number 6 or 7 is also contained between the above-mentioned antibody or its antigen-binding fragment portion and the catalytic domain portion, and the amino acids of the above-mentioned EGF-like domain corresponding to asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30 and glutamine at position 40 of pro-urokinase recorded in sequence number 6 or 7 are replaced by other amino acids, and the binding ability to the human urokinase receptor is reduced or lost.

[0039]

[24] A fusion protein comprising an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin, an EGF-like domain of prourokinase having an amino acid sequence corresponding to amino acids 7 to 43 of prourokinase as described in SEQ ID NO: 6 or 7, a kringle domain of prourokinase corresponding to amino acids 49 to 131, and a catalytic domain of prourokinase having an amino acid sequence corresponding to amino acids 156 to 411, wherein the antibody or the antigen-binding fragment thereof is linked to the catalytic domain of prourokinase directly or via a linker, wherein the fusion protein comprises:

[0040] The connector is a non-cleavable connector.

[0041] The antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region of an antibody that binds to insoluble fibrin,

[0042] An EGF-like domain having an amino acid sequence corresponding to the amino acid sequence of positions 7 to 43 of pro-urokinase recorded in sequence number 6 or 7 is also contained between the above-mentioned antibody or its antigen-binding fragment portion and the catalytic domain portion, and the amino acids of the above-mentioned EGF-like domain corresponding to asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30 and glutamine at position 40 of pro-urokinase recorded in sequence number 6 or 7 are replaced by tyrosine, serine, arginine, arginine and glutamate, respectively, and the binding ability to the human urokinase receptor is reduced or lost.

[0043]

[25] A fusion protein comprising an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin, an EGF-like domain of prourokinase having an amino acid sequence corresponding to amino acids 7 to 43 of prourokinase as described in SEQ ID NO: 6 or 7, a kringle domain of prourokinase corresponding to amino acids 49 to 131, and a catalytic domain of prourokinase having an amino acid sequence corresponding to amino acids 156 to 411, wherein the antibody or the antigen-binding fragment thereof is linked to the catalytic domain of prourokinase directly or via a linker, wherein the fusion protein comprises:

[0044] The connector is a non-cleavable connector.

[0045] The antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region of an antibody that binds to insoluble fibrin,

[0046] An EGF-like domain having an amino acid sequence corresponding to the amino acid sequence from positions 7 to 43 of pro-urokinase recorded in sequence number 6 or 7 is also contained between the above-mentioned antibody or its antigen-binding fragment portion and the catalytic domain portion, and the amino acid sequence of the above-mentioned EGF-like domain corresponding to the amino acid sequence from asparagine at position 22 to isoleucine at position 28 of pro-urokinase recorded in sequence number 6 or 7 is deleted, and the binding ability to the human urokinase receptor is reduced or preferably lost.

[0047]

[26] A fusion protein comprising an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin, an EGF-like domain of prourokinase having an amino acid sequence corresponding to amino acids 7 to 43 of prourokinase as described in SEQ ID NO: 6 or 7, a kringle domain of prourokinase corresponding to amino acids 49 to 131, and a catalytic domain of prourokinase having an amino acid sequence corresponding to amino acids 156 to 411, wherein the antibody or the antigen-binding fragment thereof is linked to the catalytic domain of prourokinase directly or via a linker, wherein the fusion protein comprises:

[0048] The connector is a non-cleavable connector.

[0049] The antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region of an antibody that binds to insoluble fibrin,

[0050] An EGF-like domain having an amino acid sequence corresponding to the amino acid sequence of positions 7 to 43 of pro-urokinase recorded in sequence number 6 or 7 is also contained between the above-mentioned antibody or its antigen-binding fragment portion and the catalytic domain portion, and the amino acid sequence of the above-mentioned EGF-like domain corresponding to the amino acid sequence of asparagine at position 22 to isoleucine at position 28 of pro-urokinase recorded in sequence number 6 or 7 is deleted, and 1 to 7 amino acids (a peptide that has no binding affinity for the human urokinase receptor, such as a peptide of 2 amino acids, such as GG) are inserted at the deleted site, and the binding ability to the human urokinase receptor is reduced or preferably lost.

[0051] [31A] A fusion protein comprising an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin and a catalytic domain of prourokinase having an amino acid sequence corresponding to the amino acid sequence from positions 156 to 411 of prourokinase as set forth in SEQ ID NO: 6 or 7, wherein the antibody or the antigen-binding fragment thereof and the catalytic domain of prourokinase are linked directly or via a linker, wherein the fusion protein:

[0052] The connector is a non-cleavable connector.

[0053] The antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region of an antibody that binds to insoluble fibrin,

[0054] The phenylalanine in the catalytic domain corresponding to the phenylalanine at position 157 of pro-urokinase described in SEQ ID NO: 6 or 7 is substituted with another amino acid.

[0055] [31B] A fusion protein comprising an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin, an EGF-like domain of prourokinase having an amino acid sequence corresponding to amino acids 7 to 43 of prourokinase set forth in SEQ ID NO: 6 or 7, and a catalytic domain of prourokinase having an amino acid sequence corresponding to amino acids 156 to 411, wherein the antibody or the antigen-binding fragment thereof is linked to the catalytic domain of prourokinase directly or via a linker, wherein the fusion protein:

[0056] The connector is a non-cleavable connector.

[0057] The antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region of an antibody that binds to insoluble fibrin,

[0058] The phenylalanine in the catalytic domain corresponding to the phenylalanine at position 157 of pro-urokinase described in SEQ ID NO: 6 or 7 is substituted with another amino acid.

[0059] [31C] A fusion protein comprising an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin, a kringle domain of prourokinase corresponding to amino acids 49 to 131 of prourokinase as described in SEQ ID NO: 6 or 7, and a catalytic domain of prourokinase having an amino acid sequence corresponding to amino acids 156 to 411, wherein the antibody or the antigen-binding fragment thereof is linked to the catalytic domain of prourokinase directly or via a linker, wherein the fusion protein:

[0060] The connector is a non-cleavable connector.

[0061] The antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region of an antibody that binds to insoluble fibrin,

[0062] The phenylalanine in the catalytic domain corresponding to the phenylalanine at position 157 of pro-urokinase described in SEQ ID NO: 6 or 7 is substituted with another amino acid.

[0063] [31D] A fusion protein comprising an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin, an EGF-like domain of prourokinase having an amino acid sequence corresponding to amino acids 7 to 43 of prourokinase as described in SEQ ID NO: 6 or 7, a kringle domain of prourokinase corresponding to amino acids 49 to 131, and a catalytic domain of prourokinase having an amino acid sequence corresponding to amino acids 156 to 411, wherein the antibody or the antigen-binding fragment thereof is linked to the catalytic domain of prourokinase directly or via a linker, wherein the fusion protein:

[0064] The connector is a non-cleavable connector.

[0065] The antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region of an antibody that binds to insoluble fibrin,

[0066] The phenylalanine in the catalytic domain corresponding to the phenylalanine at position 157 of pro-urokinase described in SEQ ID NO: 6 or 7 is substituted with another amino acid.

[0067]

[32] The fusion protein according to

[31] (i.e., any one of [31A] to [31D]), wherein the phenylalanine is replaced by isoleucine, glutamic acid, aspartic acid or cysteine.

[0068]

[33] The fusion protein according to

[31] or

[32] above, wherein the phenylalanine is replaced by glutamic acid or aspartic acid.

[0069]

[34] The fusion protein according to any one of

[31] to

[33] above, wherein

[0070] An EGF-like domain having an amino acid sequence corresponding to the amino acid sequence of positions 7 to 43 of pro-urokinase recorded in sequence number 6 or 7 is also contained between the above-mentioned antibody or its antigen-binding fragment portion and the catalytic domain portion, and the amino acids of the above-mentioned EGF-like domain corresponding to asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30 and glutamine at position 40 of pro-urokinase recorded in sequence number 6 or 7 are replaced by other amino acids, and the binding ability to the human urokinase receptor is reduced or lost.

[0071]

[35] The fusion protein according to any one of

[31] to

[34] above, wherein

[0072] An EGF-like domain having an amino acid sequence corresponding to the amino acid sequence of positions 7 to 43 of pro-urokinase recorded in sequence number 6 or 7 is also contained between the above-mentioned antibody or its antigen-binding fragment portion and the catalytic domain portion, and the amino acids of the above-mentioned EGF-like domain corresponding to asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30 and glutamine at position 40 of pro-urokinase recorded in sequence number 6 or 7 are replaced by tyrosine, serine, arginine, arginine and glutamate, respectively, and the binding ability to the human urokinase receptor is reduced or lost.

[0073]

[36] The fusion protein according to any one of

[31] to

[34] above, wherein

[0074] An EGF-like domain having an amino acid sequence corresponding to the amino acid sequence from position 7 to position 43 of pro-urokinase recorded in SEQ ID NO: 6 or 7 is contained between the above-mentioned antibody or its antigen-binding fragment portion and the catalytic domain portion, and the amino acid sequence of the above-mentioned EGF-like domain corresponding to the amino acid sequence from asparagine at position 22 to isoleucine at position 28 of pro-urokinase recorded in SEQ ID NO: 6 or 7 is deleted (for example, 1 to 7 amino acids (at least a peptide that has no binding affinity for human urokinase receptor, preferably a peptide that has no binding affinity for human urokinase receptor and mouse urokinase receptor, for example, a 2-amino acid peptide, for example, GG) is inserted into the deletion site), and the binding ability to the human urokinase receptor is reduced or preferably lost.

[0075]

[37] A pharmaceutical preparation comprising the fusion protein according to any one of

[31] to

[36] above.

[0076]

[38] A method for producing the fusion protein described in any one of

[31] to

[36] above, comprising the following steps:

[0077] The protein-producing cells that have the nucleic acid encoding the fusion protein in an expressible manner are cultured to express the fusion protein, and the fusion protein is purified from the obtained culture.

[0078]

[39] The method according to

[38] above, wherein the culture is carried out under serum-free conditions or in the presence of less than 5% serum.

[0079]

[40] The method according to

[38] or

[39] above, wherein the purification is performed in the absence of L-arginine.

[0080]

[41] A fusion protein comprising an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin, an EGF-like domain of prourokinase having an amino acid sequence corresponding to amino acids 7 to 43 of prourokinase as described in SEQ ID NO: 6 or 7, a kringle domain of prourokinase corresponding to amino acids 49 to 131, and a catalytic domain of prourokinase having an amino acid sequence corresponding to amino acids 156 to 411, wherein the antibody or the antigen-binding fragment thereof is linked to the catalytic domain of prourokinase directly or via a linker, wherein the fusion protein:

[0081] The connector is a non-cleavable connector.

[0082] The antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region of an antibody that binds to insoluble fibrin,

[0083] The phenylalanine in the catalytic domain corresponding to the phenylalanine at position 157 of pro-urokinase described in SEQ ID NO: 6 or 7 is substituted with another amino acid,

[0084] The amino acids of the above-mentioned EGF-like domain corresponding to asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30 and glutamine at position 40 of prourokinase recorded in sequence number 6 or 7 are replaced by other amino acids, and the binding ability to the human urokinase receptor is reduced or lost.

[0085]

[42] The fusion protein according to

[41] above, wherein the phenylalanine in the catalytic domain corresponding to the phenylalanine at position 157 is substituted with an amino acid other than tyrosine.

[0086]

[43] The fusion protein according to

[41] above, wherein the phenylalanine in the catalytic domain corresponding to the phenylalanine at position 157 is replaced by isoleucine, glutamic acid, aspartic acid or cysteine.

[0087]

[44] The fusion protein according to

[41] above, wherein the phenylalanine in the catalytic domain corresponding to the phenylalanine at position 157 is glutamic acid or aspartic acid.

[0088]

[45] The fusion protein according to

[41] above, wherein the amino acids of the EGF-like domain corresponding to asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30 and glutamine at position 40 of the pro-urokinase recorded in sequence number 6 or 7 are replaced by tyrosine, serine, arginine, arginine and glutamate, respectively, and the ability to bind to the human urokinase receptor is reduced or lost.

[0089]

[46] The fusion protein according to

[42] above, wherein the amino acids of the EGF-like domain corresponding to asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30 and glutamine at position 40 of the pro-urokinase recorded in sequence number 6 or 7 are replaced by tyrosine, serine, arginine, arginine and glutamate, respectively, and the ability to bind to the human urokinase receptor is reduced or lost.

[0090]

[47] The fusion protein according to

[43] above, wherein the amino acids of the EGF-like domain corresponding to asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30 and glutamine at position 40 of the pro-urokinase recorded in sequence number 6 or 7 are replaced by tyrosine, serine, arginine, arginine and glutamate, respectively, and the ability to bind to the human urokinase receptor is reduced or lost.

[0091]

[48] ​​The fusion protein according to

[44] above, wherein the amino acids of the EGF-like domain corresponding to asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30 and glutamine at position 40 of the pro-urokinase recorded in sequence number 6 or 7 are replaced by tyrosine, serine, arginine, arginine and glutamate, respectively, and the ability to bind to the human urokinase receptor is reduced or lost.

[0092]

[61] A fusion protein according to any of the above items, wherein the antibody or its antigen-binding fragment specifically binds to insoluble fibrin (particularly, only weakly binds, and particularly preferably does not significantly bind, to one or more, preferably all, selected from the group consisting of fibrinogen, soluble fibrin, and fibrin degradation products as compared to insoluble fibrin).

[0093]

[62] A fusion protein according to any of the above items, wherein the antibody or its antigen-binding fragment is bound to a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 8.

[0094]

[63] The fusion protein according to any of the above items, wherein the antibody or its antigen-binding fragment has heavy chain CDR1 to 3 and light chain CDR1 to 3 of an antibody selected from the group consisting of the 10-102 antibody, the 34-105 antibody and the Fib-0355 antibody disclosed in WO2014 / 133093 as corresponding CDRs.

[0095]

[64] A fusion protein according to any of the above items, wherein the antibody or its antigen-binding fragment comprises a heavy chain variable region comprising a heavy chain CDR1 having the amino acid sequence recorded in sequence number 10, a heavy chain CDR2 having the amino acid sequence recorded in sequence number 11, and a heavy chain CDR3 having the amino acid sequence recorded in sequence number 12, and a light chain variable region comprising a light chain CDR1 having the amino acid sequence recorded in sequence number 13, a light chain CDR2 having the amino acid sequence recorded in sequence number 14, and a light chain CDR3 having the amino acid sequence recorded in sequence number 15.

[0096]

[65] A fusion protein according to any of the above items, wherein the antibody or its antigen-binding fragment contains a heavy chain variable region having an amino acid sequence of the amino acid sequence recorded in sequence number 16, and a light chain variable region having an amino acid sequence of the amino acid sequence recorded in sequence number 17.

[0097]

[66] The fusion protein according to any of the above items, which comprises a heavy chain variable region comprising a heavy chain CDR1 having the amino acid sequence recorded in sequence number 18, a heavy chain CDR2 having the amino acid sequence recorded in sequence number 19, and a heavy chain CDR3 having the amino acid sequence recorded in sequence number 20, and a light chain variable region comprising a light chain CDR1 having the amino acid sequence recorded in sequence number 21, a light chain CDR2 having the amino acid sequence recorded in sequence number 22, and a light chain CDR3 having the amino acid sequence recorded in sequence number 23.

[0098]

[67] A fusion protein according to any of the above items, wherein the antibody or its antigen-binding fragment contains a heavy chain variable region having an amino acid sequence of the amino acid sequence recorded in SEQ ID NO: 24, and a light chain variable region having an amino acid sequence of the amino acid sequence recorded in SEQ ID NO: 25.

[0099]

[68] A fusion protein according to any of the above items, wherein the antibody or its antigen-binding fragment competes with a reference antibody for binding to insoluble fibrin, and the reference antibody contains a heavy chain variable region having an amino acid sequence of the amino acid sequence recorded in sequence number 16, and a light chain variable region having an amino acid sequence of the amino acid sequence recorded in sequence number 17.

[0100]

[69] A fusion protein according to any of the above items, wherein the antibody or its antigen-binding fragment competes with a reference antibody for binding to insoluble fibrin, and the reference antibody contains a heavy chain variable region having an amino acid sequence of the amino acid sequence recorded in sequence number 24, and a light chain variable region having an amino acid sequence of the amino acid sequence recorded in sequence number 25.

[0101]

[70] The fusion protein according to any of the above items, which has the amino acid sequence of sequence number 107.

[0102]

[71] The fusion protein according to any one of the above items, wherein the antibody or antigen-binding fragment thereof has 10 -6 M or less, 10 -7 Below M or 10 -8 The binding dissociation constant (KD) is below M.

[0103]

[72] A fusion protein according to any of the above items, wherein the antibody or its antigen-binding fragment is a Fab fragment or a Fab' fragment {herein, it can be preferably a fusion protein formed by linking the C-terminus of the heavy chain of the above fragment to the N-terminus of pro-urokinase or a part thereof or a mutant thereof}.

[0104]

[81] The fusion protein according to any of the above items has any one or more, preferably two or more, more preferably three or more, and even more preferably all of the following properties selected from the group consisting of: (i) binding specificity for insoluble fibrin; (ii) binding affinity for insoluble fibrin; (iii) resistance to inhibition caused by plasminogen activator inhibitor (PAI-1); and (iv) low induction of substrate metalloproteinase (MMP) activity in tissue surrounding thrombus.

[0105]

[82] A fusion protein according to any of the above items, which is linked to an imaging agent.

[0106]

[91] A pharmaceutical preparation comprising the fusion protein described in any one of the above items.

[0107]

[92] The pharmaceutical preparation according to the above-mentioned

[91] , which is used for treating thrombosis.

[0108]

[93] The pharmaceutical preparation according to

[91] above, which is used for treating a condition or disease in which dissolution of a fibrin clot is an appropriate therapeutic method.

[0109]

[94] The pharmaceutical preparation according to the above

[91] , which is used for treating cerebrovascular disorders and cardiovascular disorders accompanied by thrombosis.

[0110]

[95] The pharmaceutical preparation according to

[91] above, which is used for treating conditions or symptoms associated with thrombosis in cerebrovascular disorders and cardiovascular disorders.

[0111]

[96] The pharmaceutical preparation according to

[91] above, which is used to treat the state or symptoms of cerebrovascular disorder and cardiovascular disorder.

[0112]

[97] The pharmaceutical preparation according to the above-mentioned

[91] , which is used for treating ischemic cerebrovascular disorder.

[0113]

[98] The pharmaceutical preparation according to the above-mentioned

[91] , which is used for treating any one of cerebral infarction and transient ischemic attack.

[0114]

[99] The pharmaceutical preparation according to the above-mentioned

[91] , which is used for treating ischemic cardiovascular disorders.

[0115]

[100] The pharmaceutical preparation according to the above-mentioned

[91] , which is used for treating any one of angina pectoris and myocardial infarction.

[0116]

[101] The pharmaceutical preparation according to any one of

[91] to

[100] above, which is used to treat a disease in an acute phase.

[0117]

[102] The pharmaceutical preparation according to the above-mentioned

[91] , which is used for dissolving a fibrin clot in a subject having a fibrin clot.

[0118]

[103] A pharmaceutical preparation for detecting thrombus in vivo, the pharmaceutical preparation containing the fusion protein described in

[82] above.

[0119]

[104] The pharmaceutical preparation according to

[103] above, which is also used for the pharmaceutical use specified in any one of

[92] to

[102] above. BRIEF DESCRIPTION OF THE DRAWINGS

[0120] Figure 1 The graph shows the reactivity of AMU1114 variants (particularly variants of F157 of the urokinase moiety) to substrates. The vertical axis represents absorbance at 405 nm.

[0121] Figure 2 The graph shows the reactivity of AMU1114 modified forms (particularly modified forms of F157 in the urokinase moiety) to substrates after plasmin treatment. The vertical axis represents absorbance at 405 nm.

[0122] Figure 3A The figure shows the SDS-PAGE electrophoresis results of AMU1114 variants (especially the F157 variant of the urokinase part) after incubation in PBS at 37°C for 0 hours.

[0123] Figure 3B The figure shows the SDS-PAGE electrophoresis results of AMU1114 variants (especially the F157 variant of the urokinase part) after incubation in PBS at 37°C for 24 hours.

[0124] Figure 3C The figure shows the SDS-PAGE electrophoresis results of AMU1114 variants (especially the F157 variant of the urokinase part) after incubation in PBS at 37°C for 120 hours.

[0125] Figure 4 The graph shows the reactivity of AMU1114 modified forms after plasmin treatment to substrates. The vertical axis represents absorbance at 405 nm.

[0126] Figure 5 The graph shows the reactivity of AMU1114 modified forms for human urokinase receptor or mouse urokinase receptor to substrates. The vertical axis represents absorbance at 405 nm.

[0127] Fig. 6A Shown is a gel filtration chromatogram of urokinase expressed and purified in Chinese hamster ovary (CHO) cells in the presence of various concentrations of fetal bovine serum (FBS).

[0128] Figure 6BShown are the results of electrophoresis of urokinase expressed and purified in Chinese hamster ovary (CHO) cells in the presence of various concentrations of fetal bovine serum (FBS).

[0129] Fig. 7A Shown are the electrophoresis results of AMU1114 expressed and purified in Chinese hamster ovary (CHO) cells in the presence or absence of 20% FBS.

[0130] Figure 7B Shown are the electrophoresis results of AMU1114 variants expressed and purified in Chinese hamster ovary (CHO) cells in the absence of serum (in serum-free medium).

[0131] Fig. 8A Shown is a gel filtration chromatogram of AMU1114 expressed and purified in Chinese hamster ovary (CHO) cells in the absence of serum (in serum-free medium).

[0132] Figure 8B Shown is a gel filtration chromatogram of AMU1114 variants expressed and purified in Chinese hamster ovary (CHO) cells in the absence of serum (in serum-free medium).

[0133] Fig. 9 The alignment of AMU1114 and its variants is shown.

[0134] Fig.10 The graph shows the reactivity of AMU1114 modified forms after plasmin treatment to substrates. The vertical axis represents absorbance at 405 nm.

[0135] Fig.11 The graph shows the reactivity of AMU1114 modified forms for human urokinase receptor or mouse urokinase receptor to substrates. The vertical axis represents absorbance at 405 nm.

[0136] Fig. 12A These are lung tissue staining images of thrombin thrombosis model mice that received PBS, AMU1114 (Δ22-28, F157E) (0.08 mg / kg body weight or 0.32 mg / kg body weight; denoted as Amu0.08 and Amu0.32, respectively) or tenecteplase (0.05 mg / kg body weight or 0.2 mg / kg body weight; denoted as Tene0.05 and Tene0.2, respectively).

[0137] Fig. 12B This is a graph showing the total signal area corresponding to the thrombus. DETAILED DESCRIPTION

[0138] In the present specification, the "subject" is a mammal, for example, a dog, a cat, a cow, a horse, a pig, a primate (for example, a monkey, a gorilla, an orangutan, a bonobo, a chimpanzee, and a human), for example, a human.

[0139] In this specification, "fibrin" refers to an insoluble coagulation formed by cutting off the C-terminal of the three polypeptide chains (Aα chain, Bβ chain and γ chain) constituting fibrinogen. In this specification, fibrin is sometimes referred to as insoluble fibrin. More specifically, the C-terminal of fibrinogen is cut off and becomes a state called a fibrin monomer, and the fibrin monomer polymerizes under the action of calcium to form a poorly soluble fibrin polymer. The fibrin polymer is cross-linked between polymers under the action of factor XIII to form stabilized fibrin (insoluble fibrin or fibrin gel defined in this specification). Insoluble fibrin can be decomposed by plasmin. Plasmin is contained in plasma in the form of plasminogen as a precursor. When the peptide between Arg-Val of plasminogen is decomposed by plasminogen activators (such as urokinase, tissue plasminogen activator and streptokinase), plasminogen produces plasmin. Plasmin can be inhibited by proteins called plasmin inhibitors to limit its action.

[0140] The Aα chain of fibrinogen may be the Aα chain of human fibrinogen. Examples of the Aα chain of human fibrinogen include the Aα chain of human fibrinogen having an amino acid sequence registered as GenBank Accession No. AAI01936.1 and the Aα chain of human fibrinogen having an amino acid sequence corresponding to the amino acid sequence.

[0141] The Bβ chain of fibrinogen may be the Bβ chain of human fibrinogen. Examples of the Bβ chain of human fibrinogen include the human fibrinogen β chain having an amino acid sequence registered as NCBI Reference No. NP_005132.2 and the human fibrinogen β chain having an amino acid sequence corresponding to the amino acid sequence.

[0142] The fibrinogen γ chain may be a human fibrinogen γ chain. Examples of the human fibrinogen γ chain include a human fibrinogen γ chain having an amino acid sequence registered as GenBank Accession No. AAH07044.1 and a human fibrinogen γ chain having an amino acid sequence corresponding to the amino acid sequence.

[0143] In this specification, "urokinase" is one of the serine proteases called urokinase-type plasminogen activator (uPA) (for example, it can be an enzyme registered as EC 3.4.21.73). Urokinase is produced in the form of prourokinase as a precursor, and the peptide bond between Lys158-Ile159 is cut to form active urokinase (the cut chains are connected to each other by disulfide bonds). Urokinase has three domains, namely, an EGF-like domain, a kringle domain, and a catalytic domain. In addition, Lys135-Lys136 is cut, and urokinase becomes a low-molecular urokinase. It should be noted that the amino acid numbering of prourokinase is specified based on the amino acid sequence after the signal peptide of prourokinase is cut (for example, the amino acid sequence recorded in sequence number 6). As prourokinase, for example, human prourokinase can be listed. As human prourokinase, for example, human prourokinase having an amino acid sequence registered with GenBank accession number: AAA61253.1 and human prourokinase having an amino acid sequence corresponding to the amino acid sequence can be listed. In the amino acid sequence registered with GenBank accession number: AAA61253.1, the amino acid sequence at positions 1 to 20 corresponds to the signal peptide. The EGF-like domain may have a prourokinase sequence corresponding to positions 7 to 43 of the amino acid sequence recorded in sequence number 6, the kringle domain may have a prourokinase sequence corresponding to positions 49 to 131 of the amino acid sequence recorded in sequence number 6, and the catalytic domain may have a prourokinase sequence corresponding to positions 136 to 403. Various prourokinases may be used as long as they have the ability to be activated by plasmin and kallikrein into a double-chain prourokinase and to decompose plasminogen and convert it into plasmin.

[0144] In the present specification, regarding the term "corresponding to", when the second amino acid sequence has a sequence identity of 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more with the first amino acid sequence and has the same function as the peptide having the first amino acid sequence (for example, in the case of urokinase, the ability to decompose plasminogen and convert it into plasmin), it has a sequence corresponding to the first amino acid sequence.

[0145] In this specification, "antibody" refers to immunoglobulin. Antibodies can be antibodies of various isotypes, such as IgG. Antibodies can be preferably monoclonal antibodies. Antibodies can be human chimeric antibodies, humanized antibodies or human antibodies. Human chimeric antibodies can be made by replacing the constant region of a non-human antibody with the constant region of a human antibody. Humanized antibodies can be made by replacing the 6 CDRs of a human antibody with the 6 corresponding CDRs of a non-human antibody. Human antibodies can be made using animals (such as mice) in which at least the heavy chain variable region of an immunoglobulin is replaced with the corresponding region of a human locus. When the constant region is non-human, human antibodies can be obtained by replacing the constant region with the amino acid sequence of a human antibody. In this specification, antibodies can be preferably humanized antibodies. In this specification, antibodies can be preferably human antibodies. For antibodies, they have a signal peptide when produced in cells, but the signal peptide is removed when secreted outside the cell. Therefore, when administered as a drug, antibodies do not require a signal peptide.

[0146] In this specification, "CDR" refers to the complementary determining region present in the heavy chain variable region and the light chain variable region of an antibody. There are three CDRs in each of the heavy chain and light chain variable regions, which are referred to as CDR1, CDR2, and CDR3 from the N-terminus. CDRs can be determined, for example, based on the numbering of Kabat et al. (Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th ed., 1991, Bethesda: US Dept. of Health and Human Services, PHS, NIH.).

[0147] In this specification, "antigen-binding fragment of an antibody" refers to a fragment of an antibody fragment that maintains binding to an antigen. Examples of antigen-binding fragments include Fab, Fab', F(ab')2, Fv, scFv (single-chain Fv), bispecific antibodies, and sc(Fv)2 (single-chain (Fv)2). For example, Fab can be obtained by digesting an antibody with papain. Alternatively, F(ab')2 can be obtained by digesting an antibody with pepsin, and Fab' can be obtained by further reducing it. Antigen-binding fragments of other antibodies can also be prepared by methods known to those skilled in the art. In the present invention, such antigen-binding fragments of antibodies can be used.

[0148] In this specification, "fusion protein" refers to a protein formed by connecting two or more peptides from different proteins through peptide bonds. In this specification, the fusion protein of the first peptide and the second peptide may contain a third peptide and a further peptide within the scope of not significantly reducing the function of the invention, or may only contain the first peptide and the second peptide. In this specification, regarding the fusion protein of the first peptide and the second peptide, within the scope of not significantly reducing the function of the invention, it may be any of a fusion protein containing the first peptide and the second peptide in sequence and a fusion protein containing in a different order from this, preferably a fusion protein containing the first peptide and the second peptide in sequence. In the fusion protein, two or more peptides from different proteins may be connected with the aid of a joint within the scope of not significantly reducing the function of the invention, or may be connected without the aid of a joint. In the case of a joint, the joint may be a flexible joint.

[0149] <Recombinant fusion protein of the present invention>

[0150] (A) According to the present invention, a fusion protein is provided, which comprises an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin and a catalytic domain of prourokinase having an amino acid sequence corresponding to the amino acid sequence of positions 136 to 403 of prourokinase recorded in SEQ ID NO: 6, wherein the antibody or the antigen-binding fragment thereof is linked to the catalytic domain of the prourokinase directly or via a linker. Here, either or both (preferably both) of the lysine at position 135 and the lysine at position 136 of the amino acid sequence corresponding to the amino acid sequence of positions 136 to 403 of prourokinase recorded in SEQ ID NO: 6 are substituted with other amino acids, thereby inhibiting the cleavage of the catalytic domain from prourokinase. In a preferred embodiment, both of the amino acids corresponding to the lysine at position 135 and the lysine at position 136 of prourokinase recorded in SEQ ID NO: 6 are substituted with glycine. Therefore, in a particularly preferred embodiment, the prourokinase or a portion thereof of the fusion protein may have an amino acid sequence corresponding to the amino acid sequence of the mutant of prourokinase of SEQ ID NO: 7 or a portion thereof.

[0151] Before the fusion protein of the present invention binds to insoluble fibrin, the prourokinase portion is inactive. When it binds to insoluble fibrin, the prourokinase portion is cleaved by plasmin present nearby, generating double-chain urokinase, which is activated and cleaves nearby plasminogen to generate a large amount of plasmin. Thus, insoluble fibrin is effectively dissolved.

[0152] According to the present invention, the pro-urokinase of the fusion protein may further have a kringle domain. Pro-urokinase may further have an EGF-like domain and a kringle domain. In a preferred embodiment, the fusion protein has an EGF-like domain, a kringle domain and a catalytic domain in sequence. In a more preferred embodiment, the fusion protein has a region of pro-urokinase corresponding to positions 7 to 403 of the amino acid sequence recorded in sequence number 6 or 7. In a most preferred embodiment, the fusion protein may contain a pro-urokinase portion having an amino acid sequence corresponding to the amino acid sequence recorded in sequence number 6 or 7.

[0153] According to the present invention, the fusion protein contains an antibody or antigen-binding fragment thereof that binds to insoluble fibrin. The antibody or antigen-binding fragment thereof that binds to insoluble fibrin may contain a heavy chain variable region and a light chain variable region of an antibody or antigen-binding fragment thereof that binds to insoluble fibrin.

[0154] According to the present invention, the antibody or antigen-binding fragment thereof that binds to insoluble fibrin of the fusion protein may be a Fab fragment or a Fab' fragment. In one embodiment, the heavy chain variable region of the Fab fragment or the Fab' fragment is linked to pro-urokinase or a portion thereof in the above manner. In one embodiment, the light chain variable region of the Fab fragment or the Fab' fragment is linked to pro-urokinase or a portion thereof in the above manner.

[0155] In this specification, when used in the context of an antigen-binding fragment, the terms “heavy chain” and “light chain” refer to either the “heavy chain” or the “light chain” derived from the source antibody, and do not refer to the molecular weight of the antigen-binding fragment.

[0156] In a preferred embodiment of the present invention, the phenylalanine in the catalytic domain corresponding to the 157th phenylalanine in prourokinase described in SEQ ID NO: 6 in the fusion protein is substituted with another amino acid.

[0157] (B) Therefore, according to the present invention, a fusion protein is provided, which contains an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin and a catalytic domain of pro-urokinase having an amino acid sequence corresponding to the amino acid sequence from positions 136 to 403 of pro-urokinase recorded in sequence number 7, wherein the above-mentioned antibody or the antigen-binding fragment thereof is connected to the catalytic domain of the above-mentioned pro-urokinase directly or via a linker, and the phenylalanine in the above-mentioned catalytic domain corresponding to the phenylalanine at position 157 of the pro-urokinase recorded in sequence number 7 is replaced by other amino acids.

[0158] (C) In a preferred embodiment, according to the present invention, there is provided a fusion protein comprising an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin and a region of pro-urokinase having an amino acid sequence corresponding to the amino acid sequence from positions 7 to 403 of pro-urokinase recorded in SEQ ID NO: 7, wherein the antibody or the antigen-binding fragment thereof is linked to the catalytic domain of the pro-urokinase directly or via a linker, and the phenylalanine in the catalytic domain corresponding to the phenylalanine at position 157 of pro-urokinase recorded in SEQ ID NO: 7 is replaced with another amino acid. In a more preferred embodiment, the region of pro-urokinase may contain a region of pro-urokinase having an amino acid sequence corresponding to the amino acid sequence from positions 1 to 411 of pro-urokinase recorded in SEQ ID NO: 7.

[0159] According to the present invention, the phenylalanine is replaced with various amino acids (such as amino acids other than tyrosine). Thus, the fusion protein of the present invention preferably can improve the resistance to the cutting of proteolytic enzymes (such as plasmin). In a preferred embodiment, the phenylalanine is replaced with alanine, lysine, cysteine, serine, isoleucine, glycine, glutamic acid or aspartic acid. In a more preferred embodiment, the phenylalanine is replaced with isoleucine, glycine, glutamic acid or aspartic acid. Thus, the decomposition of the fusion protein and the activation associated therewith during the expression of the fusion protein, the purification of the fusion protein and / or the storage of the fusion protein can be suppressed. In a further preferred embodiment, the phenylalanine is replaced with glutamic acid or aspartic acid. Thus, in addition to suppressing the decomposition of the fusion protein and the activation associated therewith during the expression of the fusion protein, the purification of the fusion protein and / or the storage of the fusion protein, the activation in the presence of plasmin can also exert the same plasminogen decomposition activity as the fusion protein in which the phenylalanine is not replaced. In addition, when a fusion protein without the above-mentioned phenylalanine substitution is produced by a protein-expressing cell, a fragmented fusion protein is produced. However, by replacing the above-mentioned phenylalanine in the above-mentioned fusion protein with an amino acid other than tyrosine, preferably with glutamic acid or aspartic acid, even if the protein-expressing cell expressing the above-mentioned fusion protein is cultured in a low-serum medium (for example, containing only 5% or less serum) or a serum-free medium, the amount of fragmented fusion protein can be kept from increasing or reduced. In addition, when a fusion protein without the above-mentioned phenylalanine substitution is produced by a protein-expressing cell, although the amount of fusion protein produced continues to increase for 5 to 7 days, the amount of fusion protein produced does not increase beyond this time, and the proportion of light chains in the produced protein increases. In contrast, by replacing the above-mentioned phenylalanine in the above-mentioned fusion protein with an amino acid other than tyrosine, preferably with glutamic acid or aspartic acid, the proportion of light chains in the produced protein can be reduced. In addition, by replacing the phenylalanine in the fusion protein with an amino acid other than tyrosine, preferably with glutamic acid or aspartic acid, the production of the fusion protein continues to increase even for more than 7 days, thereby significantly increasing the production of the fusion protein (for example, 3 to 5 times) compared to the fusion protein without the replacement. When the use of serum can be reduced or avoided, the fluctuation of protein production caused by the fluctuation of serum quality can be suppressed, and the cost of culture is reduced, which may be beneficial.

[0160] Therefore, the operation of replacing the phenylalanine in the above-mentioned catalytic domain corresponding to the phenylalanine at position 157 of pro-urokinase recorded in sequence number 7 in the fusion protein with other amino acids, especially with glutamic acid or aspartic acid, is of great significance from the perspective of increasing yield, increasing purity and / or reducing costs in manufacturing.

[0161] (D) In ​​a preferred embodiment of the present invention, a fusion protein is provided, which comprises an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin and a region of pro-urokinase having an amino acid sequence corresponding to the amino acid sequence from positions 7 to 403 of pro-urokinase recorded in SEQ ID NO: 7, wherein the antibody or the antigen-binding fragment thereof is linked to the catalytic domain of the pro-urokinase directly or via a linker, and the phenylalanine of the catalytic domain corresponding to the phenylalanine at position 157 of pro-urokinase recorded in SEQ ID NO: 7 is replaced with glutamic acid or aspartic acid. In a preferred embodiment, the region of pro-urokinase has an amino acid sequence corresponding to the amino acid sequence from positions 1 to 411 of pro-urokinase recorded in SEQ ID NO: 7.

[0162] <Further modifications of the fusion protein of the present invention>

[0163] According to the present invention, there is provided a modified form of a fusion protein, the binding affinity of which to the urokinase receptor is reduced compared with the above-mentioned fusion protein.

[0164] Specifically, in the further modified body of the present invention, in the amino acid sequence of any one of the above fusion proteins (e.g., any one of (A) to (D)), the amino acid of the above EGF-like domain corresponding to the tryptophan at position 30 of prourokinase described in SEQ ID NO: 6 or 7 is substituted with another amino acid (particularly arginine). As a result, the binding affinity of the further modified body of the present invention to the human urokinase receptor is reduced compared with the above fusion protein.

[0165] In addition, in a further modified form of the present invention, in the amino acid sequence of any one of the above fusion proteins (e.g., any one of (A) to (D)), the amino acids of the above EGF-like domain corresponding to asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30, and glutamine at position 40 of prourokinase described in SEQ ID NO: 6 or 7 are substituted with other amino acids. As a result, the binding affinity of the further modified form of the present invention to the human urokinase receptor is reduced compared with the above fusion protein.

[0166] In one embodiment, in a further modified form of the present invention, in the amino acid sequence of any of the above fusion proteins (e.g., any of (A) to (D)), the amino acids of the above EGF-like domain corresponding to asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30, and glutamine at position 40 of pro-urokinase described in SEQ ID NO: 6 or 7 are substituted with tyrosine, serine, arginine, arginine, and glutamic acid, respectively. As a result, the binding affinity of the further modified form of the present invention to the human urokinase receptor is reduced compared with the above fusion protein.

[0167] In one embodiment, in the further modified body of the present invention, the amino acids of the EGF-like domain corresponding to the asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30, and glutamine at position 40 of pro-urokinase described in SEQ ID NO: 6 or 7 in the amino acid sequence of the fusion protein (A) are substituted with tyrosine, serine, arginine, arginine, and glutamic acid, respectively. As a result, the binding affinity of the further modified body of the present invention to the human urokinase receptor is reduced compared with the above fusion protein.

[0168] In one embodiment, in the further modified body of the present invention, the amino acids of the EGF-like domain corresponding to the asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30, and glutamine at position 40 of pro-urokinase described in SEQ ID NO: 6 or 7 in the amino acid sequence of the fusion protein (B) are substituted with tyrosine, serine, arginine, arginine, and glutamic acid, respectively. As a result, the binding affinity of the further modified body of the present invention to the human urokinase receptor is reduced compared with the above fusion protein.

[0169] In one embodiment, in the further modified body of the present invention, the amino acids of the EGF-like domain corresponding to the asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30, and glutamine at position 40 of pro-urokinase described in SEQ ID NO: 6 or 7 in the amino acid sequence of the fusion protein (C) are substituted with tyrosine, serine, arginine, arginine, and glutamic acid, respectively. As a result, the binding affinity of the further modified body of the present invention to the human urokinase receptor is reduced compared with the above fusion protein.

[0170] In one embodiment, in the further modified body of the present invention, the amino acids of the EGF-like domain corresponding to the asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30, and glutamine at position 40 of pro-urokinase described in SEQ ID NO: 6 or 7 in the amino acid sequence of the fusion protein (D) are substituted with tyrosine, serine, arginine, arginine, and glutamic acid, respectively. As a result, the binding affinity of the further modified body of the present invention to the human urokinase receptor is reduced compared with the above fusion protein.

[0171] In one embodiment, in a further modified body of the present invention, the amino acid sequence of the EGF-like domain corresponding to the amino acid sequence of asparagine at position 22 to isoleucine at position 28 of pro-urokinase described in SEQ ID NO: 6 or 7 is deleted in the amino acid sequence of any of the above fusion proteins (e.g., any of (A) to (D)). It is believed that the ability of the modified body to bind to the urokinase receptor is lost by this. In one embodiment, in a further modified body of the present invention, the amino acid sequence of the EGF-like domain corresponding to the amino acid sequence of asparagine at position 22 to isoleucine at position 28 of pro-urokinase described in SEQ ID NO: 6 or 7 is deleted in the amino acid sequence of any of the above fusion proteins (e.g., any of (A) to (D)). The deletion site has an insertion of 1 to 7 amino acids (at least a peptide having no binding affinity to human urokinase receptor, preferably a peptide having no binding affinity to human urokinase receptor and mouse urokinase receptor, for example, a 2-amino acid peptide, for example, GG). The amino acid sequence can be inserted to reduce the shortening of the protein length caused by the deletion. The inserted amino acid sequence does not need to exert a special activity and can be composed of or contain neutral amino acids such as G and S. Thus, the further modified body of the present invention does not have a significant binding affinity to the human urokinase receptor (especially the human urokinase receptor and the mouse urokinase receptor) or further reduces the binding affinity of the above-mentioned fusion protein to the receptor, preferably does not have a significant binding affinity to the human urokinase receptor and the mouse urokinase receptor.

[0172] The binding affinity to the urokinase receptor of human etc. can be less than 1 / 2, less than 1 / 3, less than 1 / 4, less than 1 / 5, less than 1 / 6, less than 1 / 7, less than 1 / 8, less than 1 / 9, less than 1 / 10, less than 1 / 20, less than 1 / 30, less than 1 / 40, less than 1 / 50, less than 1 / 60, less than 1 / 70, less than 1 / 80, less than 1 / 90 or less than 1 / 100 compared to the fusion protein recorded in SEQ ID NO: 1. The binding affinity can be determined by an ELISA test to measure the binding amount of the fusion protein on a plate with the urokinase receptor immobilized thereon, and can be obtained by subtracting the value (background) based on the negative control (e.g., phosphate buffered saline (PBS)). In the ELISA test, the binding amount of the fusion protein to the urokinase receptor can be detected by an enzyme-labeled antibody. As the enzyme-labeled antibody, an antibody that binds to the fusion protein (eg, anti-human heavy chain or light chain antibody) can be used, as the enzyme, for example, horseradish peroxidase (HRP) can be used, and as the substrate, 3,3',5,5'-tetramethylbenzidine (TMB) can be used.

[0173] Therefore, even if the fusion protein of the present invention is exposed around a thrombus, it will not bind to the urokinase receptor in the surrounding tissue, and can inhibit the production of MMP enzymes in the tissue and prevent tissue damage. It is believed that the undesirable side effects caused by binding to the urokinase receptor can be prevented.

[0174] In the modified body of the fusion protein of the present invention, the antibody or its antigen-binding fragment part binds to insoluble fibrin. In a preferred embodiment, in the modified body of the fusion protein of the present invention, the antibody or its antigen-binding fragment part specifically binds to insoluble fibrin. Here, "specifically binds to insoluble fibrin" means: binds to insoluble fibrin, but only weakly binds to one or more, preferably all, selected from the group consisting of fibrinogen, soluble fibrin and fibrin degradation products, and particularly preferably does not significantly bind to insoluble fibrin.

[0175] In the present invention, an antibody that binds to insoluble fibrin is an antibody that binds to insoluble fibrin with a stronger affinity than to fibrinogen (i.e., with a lower dissociation constant K than to fibrinogen). D Antibodies that bind to insoluble fibrin). An antibody that binds to insoluble fibrin with a stronger affinity than to fibrinogen may be, for example, an antibody that binds to a peptide consisting of an amino acid sequence recorded in sequence number 8 or 9 (see WO2014 / 133093). The amino acid sequence recorded in sequence number 8 corresponds to the amino acid sequence recorded in sequence number 1 of WO2014 / 133093, and the amino acid sequence recorded in sequence number 9 corresponds to the amino acid sequence recorded in sequence number 2 of WO2014 / 133093. The peptide portion consisting of the amino acid sequence recorded in sequence number 8 or 9 is not exposed on the protein surface of fibrinogen, but is only exposed in an antibody-accessible manner on the protein surface of insoluble fibrin. Therefore, an antibody that binds to a peptide consisting of an amino acid sequence recorded in sequence number 8 or 9 may have binding selectivity to insoluble fibrin.

[0176] <Antibody or antigen-binding fragment thereof>

[0177] Examples of antibodies or antigen-binding fragments thereof that bind to insoluble fibrin with a stronger affinity than to fibrinogen include insoluble fibrin-specific antibodies (e.g., antibodies that bind to insoluble fibrin but do not substantially bind to fibrinogen), and antibodies selected from the group consisting of the 10-102 antibodies disclosed in WO2014 / 133093 (comprising a heavy chain variable region having heavy chain CDR1 to 3 described in SEQ ID NOs: 27 to 29, respectively, and a light chain variable region having light chain CDR1 to 3 described in SEQ ID NOs: 30 to 32, respectively), and 34-105 antibodies disclosed in WO2014 / 133093. An antibody or antigen-binding fragment thereof in which the heavy chain CDR1 to 3 and light chain CDR1 to 3 of the antibody in the group consisting of an antibody (containing a heavy chain variable region having heavy chain CDR1 to 3 recorded in sequence numbers 33 to 35, respectively, and a light chain variable region having light chain CDR1 to 3 recorded in sequence numbers 36 to 38, respectively), and a Fib-0355 antibody (containing a heavy chain variable region having heavy chain CDR1 to 3 recorded in sequence numbers 39 to 41, respectively, and a light chain variable region having light chain CDR1 to 3 recorded in sequence numbers 42 to 44, respectively) are corresponding CDRs.

[0178] As antibodies or antigen-binding fragments thereof that bind to insoluble fibrin with a stronger affinity than to fibrinogen, for example, the 99 antibody disclosed in WO2018 / 203517 (comprising a heavy chain variable region having heavy chain CDR1 to 3 described in SEQ ID NOs: 45 to 47, respectively, and a light chain variable region having light chain CDR1 to 3 described in SEQ ID NOs: 48 to 50, respectively), the 1101 antibody (comprising a heavy chain CDR1 to 3 described in SEQ ID NOs: 51 to 53, respectively), and the 1102 antibody (comprising a heavy chain CDR1 to 3 described in SEQ ID NOs: 52 to 54, respectively). An antibody or antigen-binding fragment thereof in which the heavy chain CDR1 to 3 and light chain CDR1 to 3 of the antibodies in the group consisting of the heavy chain variable region having the heavy chain variable region having the heavy chain CDR1 to 3 described in sequence numbers 1 to 3 and the light chain variable region having the light chain CDR1 to 3 described in sequence numbers 54 to 56, respectively), and the 0211 antibody (containing a heavy chain variable region having the heavy chain CDR1 to 3 described in sequence numbers 57 to 59, respectively, and a light chain variable region having the light chain CDR1 to 3 described in sequence numbers 60 to 62, respectively).

[0179] As antibodies or antigen-binding fragments thereof that bind to insoluble fibrin with a stronger affinity than to fibrinogen, further examples include antibodies or antigen-binding fragments thereof that include a heavy chain CDR1 having an amino acid sequence recorded in sequence number 10, a heavy chain CDR2 having an amino acid sequence recorded in sequence number 11, and a heavy chain CDR3 having an amino acid sequence recorded in sequence number 12, and a light chain CDR1 having an amino acid sequence recorded in sequence number 13, a light chain CDR2 having an amino acid sequence recorded in sequence number 14, and a light chain CDR3 having an amino acid sequence recorded in sequence number 15. The antibody may be a human chimeric antibody or a humanized antibody. According to the present invention, a humanized antibody having the above-mentioned heavy chain variable region and light chain variable region is also provided.

[0180] As antibodies or antigen-binding fragments thereof that bind to insoluble fibrin with a stronger affinity than to fibrinogen, for example, antibodies or antigen-binding fragments thereof that contain a heavy chain variable region having an amino acid sequence of the amino acid sequence recorded in SEQ ID NO: 16 and a light chain variable region having an amino acid sequence of the amino acid sequence recorded in SEQ ID NO: 17 can be cited. In addition to containing a heavy chain variable region, the antibody may also contain a heavy chain constant region or a portion thereof in a Fab fragment. The antibody may be a human chimeric antibody or a humanized antibody. According to the present invention, a humanized antibody having the above-mentioned heavy chain variable region and light chain variable region is also provided.

[0181] As an antibody or antigen-binding fragment thereof that binds to insoluble fibrin with a stronger affinity than to fibrinogen, further examples include a heavy chain variable region comprising a heavy chain CDR1 having an amino acid sequence recorded in sequence number 18, a heavy chain CDR2 having an amino acid sequence recorded in sequence number 19, and a heavy chain CDR3 having an amino acid sequence recorded in sequence number 20, and an antibody or antigen-binding fragment thereof comprising a light chain variable region comprising a light chain CDR1 having an amino acid sequence recorded in sequence number 21, a light chain CDR2 having an amino acid sequence recorded in sequence number 22, and a light chain CDR3 having an amino acid sequence recorded in sequence number 23. The antibody may be a human chimeric antibody or a humanized antibody. According to the present invention, a humanized antibody having the above-mentioned heavy chain variable region and light chain variable region is also provided.

[0182] As antibodies or antigen-binding fragments thereof that bind to insoluble fibrin with a stronger affinity than to fibrinogen, for example, antibodies or antigen-binding fragments thereof that contain a heavy chain variable region having an amino acid sequence of the amino acid sequence recorded in SEQ ID NO: 24 and a light chain variable region having an amino acid sequence of the amino acid sequence recorded in SEQ ID NO: 25 can be cited. In addition to containing a heavy chain variable region, the antibody may also contain a heavy chain constant region or a portion thereof in a Fab fragment. The antibody may be a human chimeric antibody or a humanized antibody. According to the present invention, a humanized antibody having the above-mentioned heavy chain variable region and light chain variable region is also provided.

[0183] According to the present invention, there is provided an antibody that competes with the antibody described in (3) above for binding to insoluble fibrin, or preferably an antibody that competes with the antibody. Here, the antibody is preferably a humanized antibody.

[0184] According to the present invention, there can be provided an antibody that competes with the antibody described in (4) above for binding to insoluble fibrin, or preferably an antibody that competes with the antibody. Here, the antibody is preferably a humanized antibody.

[0185] According to the present invention, the antibody described in (1) above is a humanized antibody, and may be an insoluble fibrin-specific antibody.

[0186] According to the present invention, the antibody described in (2) above is a humanized antibody, and may be an insoluble fibrin-specific antibody.

[0187] According to the present invention, the antibody described in (3) above is a humanized antibody, and may be an insoluble fibrin-specific antibody.

[0188] According to the present invention, the antibody described in (4) above is a humanized antibody, and may be an insoluble fibrin-specific antibody.

[0189] According to the present invention, the antibody that competes with the antibody described in (3) above for binding to insoluble fibrin, and preferably the antibodies that compete with each other, are humanized antibodies, and may be insoluble fibrin-specific antibodies.

[0190] According to the present invention, the antibody that competes with the antibody described in (4) above for binding to insoluble fibrin, and preferably the antibodies that compete with each other, is a humanized antibody, and may be an insoluble fibrin-specific antibody.

[0191] The antibody of the present invention and its antigen-binding fragment portion may bind to a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 8. Here, the antibody of the present invention may be a humanized antibody.

[0192] In one embodiment, the modified body of the fusion protein of the present invention has the amino acid sequence recorded in sequence number 1. In one embodiment, the modified body of the fusion protein of the present invention has the amino acid sequence recorded in sequence number 2. In one embodiment, the modified body of the fusion protein of the present invention has the amino acid sequence recorded in sequence number 3. In one embodiment, the modified body of the fusion protein of the present invention has the amino acid sequence recorded in sequence number 26. In one embodiment, the modified body of the fusion protein of the present invention has the amino acid sequence recorded in sequence number 4. In one embodiment, the modified body of the fusion protein of the present invention has the amino acid sequence recorded in sequence number 5. In one embodiment, the modified body of the fusion protein of the present invention has the amino acid sequence recorded in sequence number 63.

[0193] <Characteristics of the modified body>

[0194] The modified body of the fusion protein of the present invention may have any one or more, preferably two or more, more preferably three or more, and further preferably all of the properties selected from the group consisting of the following: (i) binding specificity to insoluble fibrin; (ii) binding affinity to insoluble fibrin; (iii) resistance to inhibition caused by plasminogen activator inhibitor (PAI-1); and (iv) low inducibility to the activity of substrate metalloproteinases (MMPs) in tissues surrounding thrombi. Thus, a safer and more effective treatment than the previous tissue plasminogen activator (tPA) therapy can be provided. In addition, new technological innovations can be provided for thrombolytic therapy using urokinase. In particular, compared with the fusion protein disclosed in WO2021 / 200922A, it shows significant advantages in manufacturing and can play an effect of reducing side effects.

[0195] <Method for producing modified fusion protein of the present invention>

[0196] According to the present invention, a method for producing a modified body of the fusion protein of the present invention is provided. The modified body of the fusion protein of the present invention can be produced by a protein-producing cell. For example, a gene encoding the modified body can be transiently or preferably stably introduced into a protein-producing cell, and the protein-producing cell is cultured under conditions suitable for producing the modified body, thereby producing the modified body by the protein-producing cell.

[0197] Therefore, according to the present invention, a protein producing cell having a gene of a modified body encoding the fusion protein of the present invention in an expressible manner is provided. The protein producing cell may be contained in a cell cryoprotectant or in a frozen state. Therefore, according to the present invention, a cell freezing solution and a working cell bank, a master cell bank and a research cell bank containing a protein producing cell having a gene of a modified body encoding the fusion protein of the present invention in an expressible manner are provided. The modified body of the fusion protein of the present invention can be operably connected to a control sequence in particular. Thus, it can be expressed in a protein producing cell.

[0198] According to the present invention, the fusion protein of the present invention can be prepared by methods well known to those skilled in the art. For example, the fusion protein of the present invention can be expressed in cells (insect cells, avian cells, Escherichia coli, yeast and mammalian cells), preferably mammalian cells (e.g., cells suitable for protein expression, such as Chinese hamster ovary cells (CHO cells) and 293 cells and their derivatives, such as human cells and other mammalian cells suitable for protein expression). As protein-producing cells, CHO cells (e.g., ExpiCHO TM Cells, ExpiCHO-S TM Cell, Free Style TMCHO cells, etc.). Expression can be performed, for example, using an expression vector comprising a nucleic acid encoding the fusion protein of the present invention operably linked to a promoter that can be driven in the expression cell. When the fusion protein requires a light chain, the light chain can be co-expressed in the expression cell.

[0199] The modified body of the fusion protein of the present invention can be a means to solve the problem of low expression of the fusion protein in the protein-producing cells. This is because, in the case of the conventional type of fusion protein, even if the culture time is increased, the production of the fusion protein does not increase, but the production of fragments increases. In contrast, the modified body of the fusion protein of the present invention can increase the production of the modified body by increasing the culture time. Moreover, the plasminogen decomposition activity in the presence of plasmin can be equivalent to that of the conventional fusion protein.

[0200] In one embodiment, a method for producing a fusion protein variant with excellent stability or a pharmaceutical composition containing the variant is provided, which comprises the step of introducing a F157E or F157D mutation into the fusion protein of the present invention, thereby imparting excellent stability to the fusion protein before the modification. In one embodiment, a method for improving the stability of a fusion protein variant is provided, which comprises the step of introducing a F157E or F157D mutation into the fusion protein of the present invention, thereby imparting excellent stability to the fusion protein before the modification.

[0201] The culture medium can use a serum-containing culture medium, a low serum culture medium (e.g., a serum concentration of less than 5%), a serum-free culture medium, a xeno-free culture medium, or a chemically defined culture medium. From the viewpoint of impurities being mixed in, a serum-free culture medium, a xeno-free culture medium, or a chemically defined culture medium can be preferably used. The culture medium can be appropriately exchanged during cultivation. In addition, from the viewpoint of reducing production costs, a serum-free culture medium such as a serum-free culture medium, a xeno-free culture medium, or a chemically defined culture medium can be preferably used. The modified body of the fusion protein of the present invention (comprising the modification of F157) can suppress fragmentation in the absence of serum, and therefore has advantages in manufacturing compared to the non-modified body.

[0202] By adding a signal peptide to the fusion protein, the fusion protein can be produced extracellularly. Therefore, in this case, the cell culture supernatant can be recovered and the fusion protein can be recovered from the supernatant. The fusion protein can be purified using various purification techniques well known to those skilled in the art such as gel filtration and affinity purification. The modified body of the fusion protein of the present invention (including the modification of F157) is resistant to fragmentation during purification, so it is easy to manage the conditions including the temperature conditions and storage conditions during purification. For example, the fusion protein in the past needs to be purified in the presence of L-arginine, but the above-mentioned modified body can be purified in the absence of L-arginine. In addition, due to the high storage stability, the composition of the preparation can be set flexibly. In particular, the preparation does not need to include L-arginine.

[0203] The obtained modified form of the fusion protein can be immobilized on the bottom of a plate, activated with plasmin, and then the plasmin can be washed off to evaluate the plasminogen decomposition activity. For example, a plate immobilized with the activated mutant can be reacted with a substrate such as HD-valyl-L-leucyl-L-lysyl-p-nitroaniline dihydrochloride in the presence of plasminogen, and the p-nitroaniline color that develops color as the substrate decomposes can be quantitatively measured by colorimetry, thereby determining the plasminogen decomposition activity of the modified form.

[0204] <Compositions and pharmaceutical preparations>

[0205] According to the present invention, a composition or pharmaceutical preparation containing a modified body of the fusion protein of the present invention can be provided. In the composition and pharmaceutical preparation, in addition to the modified body of the fusion protein of the present invention, a pharmaceutically acceptable additive can also be contained. As additives, pH buffers, isotonic agents, salts, preservatives and analgesics can be listed. The pharmaceutical preparation can be prepared for intravenous administration or for intra-arterial administration. In one embodiment, the pharmaceutical preparation of the present invention can be a freeze-dried pharmaceutical preparation. In one embodiment, the present invention provides a kit containing a freeze-dried pharmaceutical preparation and water for injection (i.e., a kit is prepared when used).

[0206] Pharmaceutical preparations can be used to dissolve thrombi formed in the body. Therefore, pharmaceutical preparations can be used to treat thrombosis. Pharmaceutical preparations can also be used to treat states or diseases caused by thrombi. Pharmaceutical preparations can also be used to treat states or diseases for which dissolution of fibrin clots is a suitable treatment method. Pharmaceutical preparations can also be used to treat cerebrovascular disorders and cardiovascular disorders accompanied by thrombosis. Pharmaceutical preparations can, for example, treat states or symptoms caused by thrombosis in cerebrovascular disorders and cardiovascular disorders, or thereby treat states or symptoms of cerebrovascular disorders and cardiovascular disorders. Treatment includes therapeutic treatment and preventive treatment. Therapeutic treatment includes reducing the rate of deterioration of states and symptoms, reducing deterioration, stopping deterioration or improving states and symptoms, and preventive treatment includes preventing states and symptoms from occurring or reducing the incidence rate. As cerebrovascular disorders, ischemic cerebrovascular disorders can be listed. As ischemic cerebrovascular disorders, for example, cerebral infarction and transient ischemic attack can be listed. Cerebral infarction can be caused by cerebral thrombosis or cerebral embolism. Cerebral thrombosis is a state in which thrombi block cerebral blood vessels, and cerebral embolism is a state in which thrombi generated in blood vessels outside the brain are transported to the brain and block cerebral blood vessels. As cardiovascular disorders, ischemic heart disease can be cited. As ischemic heart disease, angina pectoris and myocardial infarction can be cited. The pharmaceutical preparation can be preferably used in the acute phase of these diseases. This is because, by using it in the acute phase, tissue damage caused by thrombosis and embolism can be prevented. As the acute phase, it can be an acute phase within 1 hour, within 2 hours, within 3 hours, within 4 hours, within 4.5 hours, within 5 hours, within 6 hours, within 12 hours or within 24 hours after the onset of the disease. For example, for ischemic cerebrovascular disorders, it is recommended to administer thrombolytic agents within 4.5 hours from the onset of the disease, and for ischemic cardiovascular disorders, it is recommended to administer thrombolytic agents within 6 hours from the onset of the disease. The pharmaceutical preparation of the present invention can also be used in the same way.

[0207] According to the present invention, the modified form of the fusion protein of the present invention can dissolve fibrin clots. In one embodiment, the fibrin clot is a thrombus.

[0208] <Imaging agent>

[0209] According to the present invention, the modified body of the fusion protein of the present invention can be connected to an imaging agent (including a covalent bond). The modified body and the imaging agent can be connected by a joint or directly connected without the help of a joint. The modified body connected to the imaging agent can perform imaging of fibrin clots (particularly thrombi) in vivo, which can be used to observe thrombi in vivo, for example. As imaging agents, contrast agents can be listed. Contrast agents can be contrast agents for magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) and the like. Therefore, according to the present invention, a preparation or composition for in vivo imaging is provided, which contains a modified body of the fusion protein of the present invention connected to an imaging agent.

[0210] According to the present invention, there is provided a method for treating thrombosis or dissolving fibrin clots in a subject in need thereof, comprising the step of administering a therapeutically effective amount of a modified form of the fusion protein of the present invention to the subject.

[0211] According to the present invention, a pharmaceutical preparation is provided for use in a method for treating thrombosis or a method for dissolving a fibrin clot in a subject in need thereof, wherein the pharmaceutical preparation contains a therapeutically effective amount of a modified form of the fusion protein of the present invention.

[0212] According to the present invention, a modified form of the fusion protein of the present invention is provided, which is used in a method for treating thrombosis or a method for dissolving a fibrin clot in a subject in need thereof.

[0213] According to the present invention, there is provided use of a modified form of the fusion protein of the present invention in the manufacture of a medicament for use in a method for treating thrombosis or a method for dissolving a fibrin clot in a subject in need thereof.

[0214] According to the present invention, there is provided a method for treating the state or symptoms of cerebrovascular disorder and cardiovascular disorder in a subject in need thereof, which comprises administering to the subject a therapeutically effective amount of a modified form of the fusion protein of the present invention.

[0215] According to the present invention, a pharmaceutical preparation containing a modified form of the fusion protein of the present invention is provided, which is used for a method of treating a state or symptom of a cerebrovascular disorder or a cardiovascular disorder in a subject in need thereof.

[0216] According to the present invention, there is provided a modified form of the fusion protein of the present invention for use in a method for treating a state or symptom of a cerebrovascular disorder or a cardiovascular disorder in a subject in need thereof.

[0217] Provided is a use of a modified form of the fusion protein of the present invention in the manufacture of a medicament for treating the state or symptom of cerebrovascular disorder and cardiovascular disorder in a subject in need thereof.

[0218] Example

[0219] Example 1: Preparation of fusion protein that dissolves fibrin clots

[0220] WO2021 / 200922A synthesized a fusion protein containing a fragment of an antibody that specifically binds to insoluble fibrin and a mutant of prourokinase (hereinafter referred to as "AMU1114"). AMU1114 is a complex of a fusion protein (heavy chain) formed by connecting the Fab region of an antibody and a mutant of prourokinase with the light chain of an antibody.

[0221] When Chinese hamster ovary cells (CHO cells) are made to express AMU1114, the expression level reaches a peak 5 to 7 days after the start of culture, and the expression level of AMU1114 does not increase even if the culture is continued. More specifically, Fig. 8A As shown, the production amount of AMU1114 did not increase, but the recovery amount of the light chain (L chain) increased.

[0222] The culture conditions were studied, such as Fig. 8A and 8B As shown, when AMU1114 was expressed in the CHO cells in a serum-free medium, the yield of light chain increased and the yield of AMU1114 decreased, but when AMU1114 was expressed in the CHO cells in the presence of 20% fetal bovine serum (FBS), the yield of AMU1114 increased and the yield of light chain decreased. In addition, when AMU1114 was purified from CHO cells, it was necessary to purify it in the presence of L-arginine. The recovery amount of AMU1114 after purification was 25 to 35 mg / L.

[0223] Example 2: Preparation of modified fusion protein

[0224] In this example, a modified form of AMU1114 was prepared. Specifically, a site-specific amino acid substitution mutation was introduced into F396 (corresponding to F157 of urokinase) of the heavy chain of AMU1114. The introduction of the amino acid substitution mutation was performed by PCR using a DNA encoding AMU1114 as a template and a mutation introduction primer. PrimeStar HSDNA polymerase (Takara) was used as a PCR enzyme.

[0225] AMU1114 and each PCR product integrated into pcDNA3.4 (ThermFisher) were reacted with XhoI (Takara) and NotI (Takara) for 2 hours according to the manufacturer's protocol, subjected to 1% agarose gel electrophoresis, and then purified using the FastGeneGel / PCR Extraction Kit (Nippon Genetics). Competent High DH5α (toyobo) was used for transformation and cultured in LB medium (50 μg / mL) plates for 16 hours. Plasmids were extracted from transformed E. coli using the FastGene Plasmid Mini Kit (Nippon Genetics) and sequenced. This confirmed that the mutations were introduced as intended.

[0226] AMU1114 and various mutants were expressed in CHO cells. Specifically, AMU1114 and various mutants were transiently expressed using the ExpiCHO expression system (ThermoFisher). The culture supernatant was recovered after 7 days of culture. FBS was added to the culture medium to reach 20%. The transiently expressed culture supernatant was added to CaptoL (Cytiva) equilibrated with PBS, washed with the same buffer, and eluted with 100mM glycine buffer pH 3.0 as the final product.

[0227] Each mutant was adjusted to 10 μg / mL with PBS, and 100 μL / well was dispensed into a 96-well plate, and allowed to stand at room temperature for 90 minutes for solid phase. For the plate after solid phase, 1% BSA in TBS-T was dispensed at 300 μL / well, and allowed to stand at room temperature for 60 minutes to block the plate. After washing the blocked plate with TBS-T, a reaction solution prepared by 5 μg / mL plasminogen and 15 μL / well substrate (TestzymS PLG Sekisui Medical) with PBS was added at 150 μL / well, and the absorbance at 405 nm and 505 nm was measured every 5 minutes for 2 hours.

[0228] The results are as follows Figure 1 As shown. Figure 1 As shown, except for the F157Y mutant, the reactivity to the substrate was reduced in all mutants, and the reactivity to the substrate was greatly reduced in some mutants (F157A, F157K, F157C, and F157S), and it was further clarified that the reactivity to the substrate was further reduced in some mutants (F157I, F157G, F157D, and F157E). It is believed that this is because these mutants are resistant to plasmin.

[0229] Each modified body was adjusted to 10 μg / mL with PBS, and 100 μL / well was dispensed into a 96-well plate, and allowed to stand at room temperature for 90 minutes to solidify. For the plate after solidification, 300 μL / well of TBS-T with 1% BSA was dispensed, and the plate was blocked by standing at room temperature for 60 minutes. For the blocked plate, 100 μL / well of plasmin solution adjusted to 5 μg / mL was added, and the reaction was carried out at 37°C for 60 minutes. After washing with TBS-T, 150 μL / well of the reaction solution prepared with 5 μg / mL plasminogen and 15 μL / well substrate (TestzymSPLG Sekisui Medical) with PBS was added, and the absorbance at 405 nm and 505 nm was measured every 5 minutes for 2 hours.

[0230] The results are as follows Figure 2 As shown. Figure 2As shown, all mutants showed high reactivity to the substrate when treated with plasmin. In particular, the activities of the F157E and F157D mutants were equivalent to that of AMU1114.

[0231] Each purified F157 modified form was adjusted to 1 mg / mL with PBS, and allowed to stand at 37°C. After 0 hours, the concentration of the modified form was analyzed by SDS-PAGE electrophoresis. Figure 3A ), 24 hours later ( Figure 3B ), 120 hours later ( Figure 3C ) samples for confirmation. Figures 3A to 3C In the table, various mutants are represented by the single letter symbol of the amino acid after substitution at position F157. The F157D mutant and the F157E mutant showed particularly high stability. In addition, the yield of the F157E mutant and the F157D mutant was 3 to 5 times that of AMU1114.

[0232] Example 3: Binding ability to urokinase receptor

[0233] In this example, the binding of AMU1114 to human urokinase receptor was confirmed. Since the binding was confirmed, the mutations N22Y, N27S, H29R, W30R and Q40E were further introduced into the F157D mutant and the F157E mutant, respectively (see Miyake T, et al., J Biochem. 1988; 104(4): 643-647, Magdolen V, et al., Eur J Biochem. 1996; 237(3): 743-751, and Lin L, et al., J Biol Chem. 2010; 285(14): 10982-92).

[0234] In addition, the AMU1114 mutant (N22G, K23G, Y24_I28del, F157E) was prepared by site-specific mutagenesis. Hereinafter, this mutant will be referred to as the AMU1114 (Δ22-28, F157E) mutant. The AMU1114 (Δ22-28, F157E) mutant has the amino acid sequence recorded in sequence number 63. The multiple alignment of the amino acid sequences of the prepared mutants is shown in Fig. 9 The calculated value of the yield is 100 mg / L.

[0235] As urokinase receptors, a mutant of human urokinase having the amino acid sequence of SEQ ID NO: 6 and a mouse urokinase receptor having the amino acid sequence of SEQ ID NO: 7 were used. A 6×His tag was added to the C-terminus of each urokinase and affinity purification was performed.

[0236] Specifically, for pcDNA3.3 (ThermFisher) and the PCR product of the urokinase receptor, EcoRI (Takara) and XhoI (Takara) were reacted for 2 hours according to the manufacturer's protocol, and after 1% agarose gel electrophoresis, the FastGeneGel / PCR extraction kit (Nippon Genetics) was used for purification. The vector (pcDNA3.3) and the insert were reacted for 30 minutes using Ligation High (takara). Competent High DH5α (toyobo) was used for transformation, and the plates were cultured for 16 hours using LB medium (50 μg / mL). The plasmid was extracted from the transformed Escherichia coli using the FastGene plasmid extraction kit (Nippon Genetics) for sequence analysis. The mutant of urokinase was transiently expressed using the ExpiCHO expression system (Thermo Fisher). After 12 days of culture, the culture supernatant was recovered. The culture supernatant of transient expression was dialyzed against 50 mM Tris-HCl pH 8.5, 300 mM NaCl, added to a Ni column (Cytiva) equilibrated with the same buffer, washed with the same buffer, and eluted with PBS containing 400 mM imidazole to obtain the final product.

[0237] Purification of the transformed body. AMU1114 (N22Y, N27S, H29R, W30R, Q40E, F157D) mutant, AMU1114 (N22Y, N27S, H29R, W30R, Q40E, F157E) mutant, and AMU1114 (Δ22-28, F157E) mutant were transiently expressed in serum-free medium using only the ExpiCHO expression system (Thermo Fisher). After 12 days of culture, the culture supernatant was recovered. The culture supernatant of transient expression was added to CaptoL (Cytiva) equilibrated with PBS, washed with the same buffer, and eluted with 100mM glycine buffer pH3.0. The eluted sample was purified by gel filtration using Superdex200pg (Cytiva) as the final product.

[0238] Each modified body was adjusted to 10 μg / mL with PBS, and 100 μL / well was dispensed into a 96-well plate, and allowed to stand at room temperature for 90 minutes for solid phase. For the plate after solid phase, 1% BSA in TBS-T was dispensed at 300 μL / well, and the plate was allowed to stand at room temperature for 60 minutes to block. For the blocked plate, a plasmin solution adjusted to 5 μg / mL was added at 100 μL / well, and reacted at 37°C for 60 minutes. After washing with TBS-T, a reaction solution prepared by adjusting 5 μg / mL plasminogen and 15 μL / well substrate (TestzymSPLG Sekisui Medical) with PBS was added at 150 μL / well, and the absorbance at 405 nm and 505 nm was measured every 5 minutes for 2 hours.

[0239] The results are as follows Figure 4 and 10 As shown. Figure 4 and 10 As shown, all three mutants showed equivalent reactivity to AMU1114 in the presence of plasmin.

[0240] The concentration of human and mouse urokinase receptors was adjusted to 1 μg / mL with PBS, and 50 μL / well was dispensed into a 96-well plate, and the plate was left to stand at room temperature for 90 minutes to solidify. After solidification, 300 μL / well of TBS-T containing 1% BSA was dispensed, and the plate was left to stand at room temperature for 60 minutes to block. After blocking, each sample (mutant) adjusted to 1000 ng / mL, 111.1 ng / mL, and 12.3 ng / mL was added to the blocked plate at 50 μL / well, and the plate was reacted at room temperature for 60 minutes. After washing with TBS-T, HRP-conjugated anti-human kappa chain antibody (Bethyl) diluted 1 / 50000 with TBS-T containing 1% BSA was dispensed at 50 μL / well, and the plate was reacted at room temperature for 60 minutes. After washing, the plate was reacted with TMB (3,3',5,5'-tetramethylbenzidine) colorimetric reagent for 15 minutes. The reaction was stopped with 30 μL / well of 2N H 2 SO 4 and the absorbance at 450 nm was measured.

[0241] The results are as follows Figure 5 As shown. Figure 5 As shown in Figure 1, it was first confirmed that AMU1114 has binding ability to human urokinase receptor. Therefore, the binding ability of the above three mutants to human urokinase receptor was tested. Figure 5 and 11 As shown in Figure 3, the three mutants lost their ability to bind to the mutants of human urokinase. Fig.11As shown, as can be understood from the comparison with PBS as a negative control, the AMU1114 (Δ22-28, F157E) mutant showed no significant binding to either the human urokinase receptor or the mouse urokinase receptor. Furthermore, when an AMU1114 mutant having F157E / D and W30R was prepared, the mutant also showed an extremely reduced binding to the human urokinase receptor.

[0242] Urokinase with a His tag added to the C-terminus was expressed using ExpiCHO containing 5%, 10%, and 20% FBS, respectively. The culture supernatant after 12 days of culture was dialyzed with 50mM Tris-HCl pH8.5, 300mM NaCl, added to a Ni column (Cytiva) equilibrated with the same buffer, washed with the same buffer, and eluted with PBS containing 400mM imidazole. The eluted sample was gel filtered using Superdex75pg (Cytiva) and used as the final sample.

[0243] The results are as follows Fig. 6A and 6B As shown. Fig. 6A and 6B As shown, when cells were cultured in the presence of 5% FBS, low molecular weight uPA was observed, and when cells were cultured in the presence of 20% FBS, the amount of low molecular weight uPA was observed to decrease. Therefore, it was shown that cells need to be cultured in the presence of FBS for uPA expression.

[0244] AMU1114 was similarly expressed using ExpiCHO in the presence of 20% FBS or in the absence of serum. When AMU1114 was purified and electrophoresed as described above, the presence of various fragments was confirmed in the absence of serum (see Fig. 7A ), in the presence of 20% FBS, the amount of these fragments was greatly reduced (ref. Fig. 7A ).

[0245] Then, four AMU1114 variants were expressed in ExpiCHO in the same manner under serum-free conditions. When the variants were purified and electrophoresed as described above, no fragmentation occurred when these mutants were cultured under serum-free conditions (refer to Figure 7B ).

[0246] AMU1114 and AMU1114 variants were affinity purified and analyzed by gel filtration. Fig. 8A and 8B As shown. Fig. 8A and 8BAs shown, in the case of AMU1114, the peak of the light chain was observed more strongly than the peak of AMU1114, while the AMU1114 variant suppressed the appearance of the light chain and the peak of the AMU1114 variant was relatively larger.

[0247] According to the above results, the F157 mutant of AMU1114 showed the same physiological activity as AMU1114 in the presence of plasmin, but was more stable than AMU1114 and had less contamination with free light chains, etc., so it had high purity and a production volume that was approximately 3 to 5 times higher than that of AMU1114.

[0248] AMU1114 (Δ22-28, F157E) was administered to thrombin thrombosis model mice, and the degree of thrombus dissolution was compared with that of the tenecteplase-administered group and the negative control group. Specifically, 600 U / kg of thrombin was intravenously injected into Balb / c female mice to prepare thrombin thrombosis model mice. 30 minutes after the intravenous injection, PBS (negative control), tenecteplase (positive control) and AMU1114 (Δ22-28, F157E) were intravenously administered, respectively. Furthermore, after 60 minutes, the lungs were removed from the mice under deep anesthesia, and the thrombi were stained. Staining was performed by a direct method using a labeled anti-insoluble fibrin antibody (1101 antibody). The total area of ​​the signal (brown) corresponding to the thrombus was calculated. The higher the thrombus solubility, the smaller the total area. The results are as follows. Fig. 12A and Fig. 12B As shown in Table 1, a great number of thrombi were observed in the negative control group, whereas almost no thrombi were observed in the positive control group and the AMU1114 (Δ22-28, F157E)-administered group.

[0249]

[0250] Contents of the sequence listing

[0251] SEQ ID NO: 1: Amino acid sequence of AMU1114

[0252] EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWMHWVRQMPGKGLEWIGAIYPGNSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCTRKAHYGNYGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCGSGGGGSGGGGSGGSSSNELHQVPSNCDCLNGGTCVSNKYFSNIHWCNCPKKFGGQHCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHNYCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGGGPSSPPEELKFQCGQKTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLALSAGGAS

[0253] Sequence number 2: Amino acid sequence of AMU1114 F157D

[0254] EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWMHWVRQMPGKGLEWIGAIYPGNSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCTRKAHYGNYGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCGSGGGGSGGGGSGGSSSNELHQVPSNCDCLNGGTCVSNKYFSNIHWCNCPKKFGGQHCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHNYCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGGGPSSPPEELKFQCGQKTLRPRDKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLALSAGGAS

[0255] Sequence No. 3: Amino acid sequence of AMU1114 F157E

[0256] EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWMHWVRQMPGKGLEWIGAIYPGNSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCTRKAHYGNYGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCGSGGGGSGGGGSGGSSSNELHQVPSNCDCLNGGTCVSNKYFSNIHWCNCPKKFGGQHCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHNYCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGGGPSSPPEELKFQCGQKTLRPREKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLALSAGGAS

[0257] Sequence No. 4: AMU1114 F157D, further modified amino acid sequence

[0258] EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWMHWVRQMPGKGLEWIGAIYPGNSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCTRKAHYGNYGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCGSGGGGSGGGGSGGSSSNELHQVPSNCDCLNGGTCVSYKYFSSIRRCNCPKKFGGEHCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHNYCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGGGPSSPPEELKFQCGQKTLRPRDKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLALSAGGAS

[0259] Sequence No. 5: AMU1114 F157E, Further Modified Amino Acid Sequence

[0260] EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWMHWVRQMPGKGLEWIGAIYPGNSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCTRKAHYGNYGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCGSGGGGSGGGGSGGSSSNELHQVPSNCDCLNGGTCVSYKYFSSIRRCNCPKKFGGEHCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHNYCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGGGPSSPPEELKFQCGQKTLRPREKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLALSAGGAS

[0261] Sequence No. 6: Amino acid sequence of prourokinase

[0262] SNELHQVPSNCDCLNGGTCVSNKYFSNIHWCNCPKKFGGQHCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHNYC RNPDNRRRPWCYVQVGLKPLVQECMVHDCADGKKPSSPPEELKFQCGQKTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVISATHC FIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLAL

[0263] SEQ ID NO: 7: Amino acid sequence of pro-urokinase K135G, K136G

[0264] SNELHQVPSNCDCLNGGTCVSNKYFSNIHWCNCPKKFGGQHCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHNYCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGGGPSSPPEELKFQCGQKTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVISATHC FIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLAL

[0265] SEQ ID NO. 8: Amino acid sequence of fibrinogen Bbeta 231-246 CNIPVVSGKECEEIIR

[0266] SEQ ID NO. 9: Amino acid sequence of fibrinogen gamma 232-246 KNWIQYKEGFGHLSP

[0267] SEQ ID NO: 10: Amino acid sequence of humanized 1101 HCDR1 SYWMH

[0268] SEQ ID NO: 11: Amino acid sequence of humanized 1101 HCDR2 AIYPGNSDTRYSPSFQG

[0269] SEQ ID NO: 12: Amino acid sequence of humanized 1101 HCDR3 KAHYGNYGFAY

[0270] SEQ ID NO: 13: Amino acid sequence of humanized 1101 LCDR1 RASQHINNWLA

[0271] SEQ ID NO: 14: Amino acid sequence of humanized 1101 LCDR2 GATSLQS

[0272] SEQ ID NO: 15: Amino acid sequence of humanized 1101 LCDR3 QQYWSTPLT

[0273] SEQ ID NO: 16: Amino acid sequence of humanized 1101 VH

[0274] MGSTAILALLLAVLQGVCAEVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWMHWVRQMPGKGLEWIGAIYPGNSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCTRKAHY GNYGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC

[0275] SEQ ID NO: 17: Amino acid sequence of humanized 1101 VL

[0276] MDMRVPAQLLGLLLLWLRGARCDIQMTQSPSSSLSASVGDRVTITCRASQHINNWLAWYQQKPGKAPKLLISGATSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYWSTPL TFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0277] SEQ ID NO: 18: Amino acid sequence of humanized 99 HCDR1 NYGMN

[0278] SEQ ID NO: 19: Amino acid sequence of humanized 99 HCDR2 WINTKIGEPTYAQKFQG

[0279] SEQ ID NO: 20: Amino acid sequence of humanized 99 HCDR3 LLDY

[0280] SEQ ID NO: 21: Amino acid sequence of humanized 99 LCDR1 RASQSVLYSSNQKNYLA

[0281] SEQ ID NO: 22: Amino acid sequence of humanized 99 LCDR2 WASSLQS

[0282] SEQ ID NO: 23: Amino acid sequence of humanized 99 LCDR3 HQYLSSYT

[0283] SEQ ID NO: 24: Amino acid sequence of humanized 99 VH

[0284] QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTKIGEPTYAQKFQGRVTMTRDKSSSTAYMELSSLRSEDTAVYYCARLLDYWGQGTLVTVSS

[0285] SEQ ID NO: 25: Amino acid sequence of humanized 99 VL

[0286] DIQMTQSPSSSLSASVGDRVTITCRASQSVLYSSNQKNYLAWYQQKPGKSPKLLIYWASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYLSSYTFGQGTKVEIKR

[0287] SEQ ID NO: 26: AMU1114 F157E / D, further modified amino acid sequence

[0288] EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWMHWVRQMPGKGLEWIGAIYPGNSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCTRKAHYGNYGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCGSGGGGSGGGGSGGSSSNELHQVPSNCDCLNGGTCVSYKYFSSIRRCNCPKKFGGEHCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRS DALQLGLGKHNYCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGGGPSSPPEELKFQCGQKTLRPRXKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHH NDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCAKDKPGVYTRVSHFLPWIRSHTKEENGLALSAGGAS

[0289] SEQ ID NO: 27: 10-102 HCDR1 amino acid sequence FTNYGMN

[0290] SEQ ID NO: 28: 10-102 HCDR2 amino acid sequence WINTYTGEATYA

[0291] SEQ ID NO: 29: 10-102 HCDR3 amino acid sequence LMDY

[0292] SEQ ID NO: 30: 10-102 LCDR1 amino acid sequence KASQDINKYIA

[0293] SEQ ID NO: 31: 10-102 LCDR2 amino acid sequence YTSTLQP

[0294] SEQ ID NO: 32: 10-102 LCDR3 amino acid sequence LQYDNLTW

[0295] SEQ ID NO: 33:34-105 HCDR1 amino acid sequence KSVSTSGYSY

[0296] SEQ ID NO: 34:34-105 HCDR2 amino acid sequence LVS

[0297] SEQ ID NO: 35:34-105 HCDR3 amino acid sequence QHIRELTR

[0298] SEQ ID NO: 36: Amino acid sequence of 34-105 LCDR1 GFTFSSYA

[0299] SEQ ID NO: 37: 34-105 LCDR2 amino acid sequence ISSGGTT

[0300] SEQ ID NO: 38: Amino acid sequence of 34-105 LCDR3 VRGGTIGAY

[0301] SEQ ID NO: 39: Fib-0355 HCDR1 amino acid sequence QSVLYSSNQK

[0302] SEQ ID NO: 40: Fib-0355 HCDR2 amino acid sequence YWASTRES

[0303] SEQ ID NO: 41: Fib-0355 HCDR3 amino acid sequence YLSS

[0304] SEQ ID NO: 42: Fib-0355 LCDR1 amino acid sequence YTFTNYG

[0305] SEQ ID NO: 43: Fib-0355 LCDR2 amino acid sequence NTNTGE

[0306] SEQ ID NO: 44: Fib-0355 LCDR3 amino acid sequence RLLDY

[0307] SEQ ID NO: 45:99 HCDR1 amino acid sequence NYGMN

[0308] SEQ ID NO: 46:99 HCDR2 amino acid sequence WINTKIGEPTYAEEFKG

[0309] SEQ ID NO: 47:99 HCDR3 amino acid sequence LLDY

[0310] SEQ ID NO: 48:99 LCDR1 amino acid sequence RASESVDSYGNSFMH

[0311] SEQ ID NO: 49:99 LCDR2 amino acid sequence RASNLES

[0312] SEQ ID NO: 50:99 LCDR3 amino acid sequence QQSNEDPRT

[0313] SEQ ID NO: 51: 1101 HCDR1 amino acid sequence SYWMH

[0314] SEQ ID NO: 52: 1101 HCDR2 amino acid sequence AIYPGNSDTRNNQKFKG

[0315] SEQ ID NO: 53: 1101 HCDR3 amino acid sequence KAHYGNYGFAY

[0316] SEQ ID NO: 54: 1101 LCDR1 amino acid sequence KASDHINNWLA

[0317] SEQ ID NO: 55: 1101 LCDR2 amino acid sequence GATSLET

[0318] SEQ ID NO: 56: 1101 LCDR3 amino acid sequence QQYWSTPLT

[0319] SEQ ID NO: 57:0211 HCDR1 amino acid sequence SYAMS

[0320] SEQ ID NO: 58:0211 HCDR2 amino acid sequence AISSGGTTYYPDSVKG

[0321] SEQ ID NO: 59:0211 HCDR3 amino acid sequence GGTIGAYW

[0322] SEQ ID NO: 60:0211 LCDR1 amino acid sequence KSSQSVLYSSNQKNYLA

[0323] SEQ ID NO: 61:0211 Amino acid sequence of LCDR2 WASTRES

[0324] SEQ ID NO: 62: 0211 LCDR3 amino acid sequence HQYLSSWT

[0325] SEQ ID NO: 63: Amino acid sequence of AMU1114 (Δ22-28, F157E)

[0326] EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWMHWVRQMPGKGLEWIGAIYPGNSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCTRKAHYGNYGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCGSGGGGSGGGGSGGSSSNELHQVPSNCDCLNGGTCVSGGHWCNCPKKFGGQHCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHNYCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGGGPSSPPEELKFQCGQKTLRPREKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLALSAGGAS

Claims

1. A fusion protein comprising an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin and a catalytic domain of prourokinase having an amino acid sequence corresponding to the amino acid sequence from position 156 to position 411 of prourokinase as described in SEQ ID NO: 6 or 7, wherein the antibody or the antigen-binding fragment thereof is linked to the catalytic domain of prourokinase directly or via a linker, wherein the fusion protein comprises: The antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region of an antibody that binds to insoluble fibrin, The phenylalanine in the catalytic domain corresponding to the phenylalanine at position 157 of pro-urokinase described in SEQ ID NO: 6 or 7 is substituted with another amino acid.

2. The fusion protein according to claim 1, wherein The phenylalanine is replaced with isoleucine, glutamic acid, aspartic acid or cysteine.

3. The fusion protein according to claim 1 or 2, wherein The phenylalanine is replaced with glutamic acid or aspartic acid.

4. The fusion protein according to any one of claims 1 to 3, wherein Compared to the fusion protein having the amino acid sequence described in SEQ ID NO: 1, the ability to bind to one or more urokinase receptors selected from the group consisting of human urokinase receptor and mouse urokinase receptor is reduced.

5. The fusion protein according to any one of claims 1 to 4, wherein No significant binding is shown to one or more urokinase receptors selected from the group consisting of human urokinase receptor and mouse urokinase receptor.

6. The fusion protein according to any one of claims 1 to 3, wherein An EGF-like domain having an amino acid sequence corresponding to the amino acid sequence at positions 7 to 43 of pro-urokinase recorded in sequence number 6 or 7 is also contained between the antibody or its antigen-binding fragment portion and the catalytic domain portion, and the amino acids of the EGF-like domain corresponding to asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30 and glutamine at position 40 of pro-urokinase recorded in sequence number 6 or 7 are replaced by other amino acids, thereby reducing or losing the ability to bind to the human urokinase receptor.

7. The fusion protein according to any one of claims 1 to 4, wherein An EGF-like domain having an amino acid sequence corresponding to the amino acid sequence of positions 7 to 43 of pro-urokinase recorded in sequence number 6 or 7 is also contained between the antibody or its antigen-binding fragment portion and the catalytic domain portion, and the amino acids of the EGF-like domain corresponding to asparagine at position 22, asparagine at position 27, histidine at position 29, tryptophan at position 30 and glutamine at position 40 of pro-urokinase recorded in sequence number 6 or 7 are replaced by tyrosine, serine, arginine, arginine and glutamate, respectively, and the binding ability to the human urokinase receptor is reduced or lost.

8. The fusion protein according to any one of claims 1 to 4, wherein An EGF-like domain having an amino acid sequence corresponding to the amino acid sequence at positions 7 to 43 of pro-urokinase recorded in sequence number 6 or 7 is also contained between the antibody or its antigen-binding fragment portion and the catalytic domain portion, and the amino acid deletion of the EGF-like domain corresponding to the amino acids from asparagine at position 22 to isoleucine at position 28 of pro-urokinase recorded in sequence number 6 or 7. 9 . A pharmaceutical preparation comprising the fusion protein according to claim 1 .

10. A method for producing the fusion protein according to any one of claims 1 to 8, comprising the following steps: Cultivating a protein-producing cell that has a nucleic acid encoding the fusion protein in an expressible manner to express the fusion protein; and The fusion protein is purified from the resulting culture.

11. The method according to claim 10, wherein: The culture is performed under serum-free conditions or in the presence of less than 5% serum.

12. The method according to claim 10 or 11, wherein: Purification was performed in the absence of L-arginine.

13. A method for producing a fusion protein variant with excellent stability or a pharmaceutical composition containing the variant, wherein: The fusion protein is a fusion protein comprising an antibody or an antigen-binding fragment thereof that binds to insoluble fibrin and a catalytic domain of prourokinase having an amino acid sequence corresponding to the amino acid sequence from positions 156 to 411 of prourokinase described in SEQ ID NO: 6 or 7, wherein the antibody or the antigen-binding fragment thereof and the catalytic domain of prourokinase are linked directly or via a linker, The antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region of an antibody that binds to insoluble fibrin, The method comprises the following steps: introducing F157E or F157D mutation into the fusion protein, thereby conferring better stability than the fusion protein before the modification.